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Heart transplantation (HTx) is now an established therapy for end-stage 
cardiac failure not responding to medical treatment. Recent decades have seen 
improved outcome following HTx due to more effective and targeted 
immunosuppressive therapy. However, acute and chronic rejection remains a 
major cause of morbidity and mortality. At the same time, immunosuppressive 
strategies are associated with significant side effects, including development of 
tumours. Hence, the induction of immunologic tolerance to alloantigen is 
considered the “holy grail” of transplant research.  
T regulatory cells (Tregs) are a subset of T cells that appear to suppress 
cytotoxic cell and initiate tolerance to foreign tissues. The Tregs suppress 
cytotoxic cells through specific cytokine pathways and cell-cell contact. In-vivo 
Treg migration has been a matter of debate in recent years. Treg trafficking is 
governed by chemokines, which are small secreted proteins, acting via their 
distinct trans-membrane serpentine receptors.  
Experimental work has demonstrated an involvement of distinct 
chemokine pathways in Tregs migration and localization following cardiac 
transplantation; however, there is paucity of data in humans. I investigated the 
effects of chemokines on Tregs in heart transplant recipients through a series of 
observational studies. My study demonstrated that acute rejection following 
heart transplantation is associated with a significant elevation of peripheral 
blood Th1 chemokine levels. I hereby further show that peripheral blood Treg 
counts in stable heart transplant recipients are not affected by 
immunosuppression but are significantly lower in patients taking statins. I have 
demonstrated via in-vitro chemotaxis assays a specific pattern of chemotactic 
response for Tregs and the effector T cells. Using double immunofluorescence 
staining and immunostaining, I show for the first time that Tregs may migrate to 
the allograft under the influence of CCL17.  
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Chapter 1 A review of the role of chemokines and Tregs following heart 
transplantation 
1.1 Introduction 
Clinical outcome following cardiac transplantation has significantly 
improved since its first description by Prof. Christian Barnard, who performed 
this pioneering operation on December the 3rd, 1967 in Cape Town (1). 
Although the first heart transplant recipient survived for 18 days only before 
succumbing to a chest infection; it sparked enormous interest in the medical 
community across the globe. This enthusiasm soon faded due to a poor long-
term survival owing to inadequate understanding of the early post-operative 
complications, acute rejection and coronary vasculopathy (2). The next two 
decades saw overcoming of these hurdles, with a better understanding of the 
immune response across the antigenic barrier, diagnosis for rejection and 
provision of better immunosuppressive agents (3). Current figures demonstrate 
an excellent long-term survival following heart transplantation, with the median 
survival in excess of 10 years (4). Nevertheless, acute and chronic rejections 
continue to remain a major cause of morbidity and mortality. In addition, long 
term use of various immunosuppressive agents risks the development of serious 
adverse effects, including infections and carcinomas (4). Hence, considerable 
research is focused on obtaining a state of immunological tolerance across the 
barrier of Major Histocompatibility Complex (MHC). Immunological tolerance 
is a state of antigen-specific immunological unresponsiveness towards the 
allograft, thereby avoiding rejection and allowing sustained graft function 
without the need of immunosuppressive medications.  
 19 
 
1.2 Mechanisms of transplant tolerance 
The concept of immunological tolerance emanates from the pioneering 
work by Sir Peter Medawar during World War II.  His work, which started as an 
attempt to improve the outcome of skin grafting to help the burn victims, formed 
basis of the immunological mechanisms underpinning future developments in 
solid organ transplantation (5). His elucidation of acquired immunological 
tolerance constituted part of the overall work leading to the award of Nobel 
Prize in 1960.  
The mechanisms for tolerance induction include central and peripheral 
tolerance (6). Central tolerance involves intra-thymic deletion or “negative 
selection” of T lymphocytes with high avidity for the expressed antigens. In 
contrast, there are several mechanisms for the induction of Peripheral 
tolerance, including clonal deletion, clonal anergy, exhaustion, ignorance or 
active suppression  by regulatory T cells (7). 
Clonal deletion is achieved by elimination of all those clones of T 
lymphocytes that can bind to donor-associated MHC antigens. It can be 
accomplished by thymic elimination of donor-specific T cells (central 
deletion), as seen in animal models of haematopoietic donor-chimerism (8). The 
donor T cells enter the recipient thymus, where donor-reactive T cell clones are 
deleted via apoptosis (9). Deletion of alloreactive T cells can also be achieved 
directly by depleting antibodies, immunotoxins, and /or lymphoid irradiation. 
The emigration of new alloreactive T cells following this non-selective depletion 
seems to favour, but does not insure tolerance induction (10). Therefore, the 
newly generated alloreactive T cells have to be deleted through ongoing therapy. 
 20 
Clonal exhaustion (or activation-induced cell death (AICD) is a 
method of T cell apoptosis triggered by repetitive stimulation of the activated T 
cells with high concentrations of antigen, or exposure to alloantigen in a 
suboptimal condition (11, 12). A classis example is tolerance following MHC-
mismatch liver transplantation, due to the presence of a large number of donor 
antigen presenting cells (13). 
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Figure 1.1 Mechanisms of Tolerance induction. Central tolerance refers to 
intra-thymic deletion of high-avidity lymphocytes, while the peripheral tolerance 
can be induced by several mechanisms, including T regulatory cells.  
 
 
Mechanisms of 
Tolerance
Central tolerance Peripheral tolerance
Clonal deletion Anergy Regulatory cells Peripheral deletion
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 Ignorance is a state of unresponsiveness to alloantigen, developing as a 
result of interplay between new, alloreactive T cells and immuno-regulatory 
mechanisms (14). This state of unresponsiveness to alloantigen is not a 
permanent tolerance, as is can be broken by further triggering with alloantigen 
or exposure to interleukin 2 (IL-2) (15).  
Peripheral suppression of self- or alloreactive T cells can also be 
achieved by induction of anergy. It is established that T cell activation requires 
CD28 co-stimulation when the T cell receptor (TCR) binds to peptide: MHC 
molecule. The expression of co-stimulatory molecules on the antigen presenting 
cells (APC) is tightly regulated. Therefore, when engagement of TCR (signal 1) 
occurs without co-stimulation (signal 2) T cell clones cannot proliferate or 
produce interleukin 2 (IL2), which is a necessary cytokine for T cell 
proliferation (16). Further observations suggest that this anergic state can 
develop as a result of either intrinsic signalling defects (such as a lack of 
mitogen-activated protein kinase (MAPK) signalling) or up-regulation of 
dominant anergic factors (17). Various models have been suggested to lead to 
anergic state, including oral administration of antigens, cross linking of CD3 
complexes in vitro, and use of potent calcium ionophore, ionomycin (18). 
Further work provides evidence of reduced activation of LAT (linker of 
activation of T cells), a transmembrane protein that facilitates various other 
signalling molecule, as a critical step in the induction of anergy (19). 
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1.3  Tolerance by regulatory cells 
The evidence for a peripheral T-cell mediated active immunosuppression 
was first reported by Gershon et al in 1970 (20). In 1985, Hall et al reported 
specific suppression of alloreactive cells by CD4+ T helper/inducer cells in a rat 
model of heart transplantation (21). Later, Sakaguchi et al showed it for the first 
time that CD4+ T cells co-expressing CD25 were able to prevent organ specific 
autoimmune disease (22). These “regulatory T cells” (Tregs) were mentioned 
as thymically-derived, as neo-natal thymectomy at day 3 of age led to various 
organ-specific autoimmune diseases. In turn, adoptive transfer of CD4+CD25+ T 
cells from normal mice into thymectomized animals completely prevented 
manifestations of autoimmune diseases in those animals (22, 23). In vitro studies 
suggest that these CD4+ CD25+ cells are anergic i.e. do not proliferate on 
stimulation with  exogenous IL-2 or TCR stimulation alone (24) and inhibit the 
proliferation of other CD4+ and CD8+ effector cells through a cell-cell contact 
dependent and antigen non-specific mechanism which required T cell receptor 
signaling (25, 26) and is reversible by IL-2 (27). They have also been shown to 
maintain allograft tolerance in vivo via interleukin (IL)-10 (28), and cytotoxic T-
lymphocyte associated antigen 4 (CTLA-4) dependent mechanisms (29). 
Since then it has been extensively documented that Tregs have a major role in 
maintaining tolerance in both experimental and clinical transplantation models 
(30-34).  
Tregs can be broadly classified into natural and adaptive subsets. 
Naturally occurring CD25+ T cells comprise 5-10 % of the peripheral blood 
CD4+ T cells in adult humans and mice (35-37). Originally thought to develop 
only in the thymus by positive selection of naïve T cells (38), CD4+CD25+ Tregs 
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can also be generated in the periphery from either CD25- T cells through 
costimulation with T cell receptor and transforming growth factor beta (39, 40), 
or from highly differentiated memory CD4+ T cells (41).  
The molecular properties that characterize Tregs remain a matter of 
debate. Several cell-surface molecules have been identified for this 
subpopulation of CD4+ T cells (table 1.1).  
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Table 1.1 Cell markers for Tregs. The markers are listed with their 
abbreviated and full names, while the third column shows the location of the 
marker within the cell. The last column shows that some of the cell markers are 
not specific for Tregs. CD = Cluster of Designation, IL = Interleukin.  
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Marker  Full / other 
name 
Location Comments 
CD25 IL-2 receptor α 
chain 
Cell 
membrane 
Expressed on activated T cells, high  
expression on Tregs (36, 42) 
CTLA4  cytotoxic T-
lymphocyte 
antigen 4 
(CD152) 
Intracellular 
Cell 
membrane 
Mainly intracellular, induced after  
TCR activation (43, 44), also 
expressed on activated CD25- T cells 
(45) and B cells (46). 
CD103 αEβ7 integrin Cell 
membrane 
Receptor for E-cadherin (47),  
responsible for mucosal lymphocyte  
homing (48), expressed in naïve  
(49) or effector/memory-like  
Tregs (50), also expressed on CD25-
/low
 cells (36). 
GITR Glucocorticoid 
induced tumour 
necrosis factor 
receptor family-
related gene, 
TNFRSF18 
Cell 
membrane 
Expressed on both naïve and  
activated Tregs and activated CD25- T 
cells (49, 51) ,  
expression level in humans  
were found uniformly  
distributed on all CD3+ and  
CD4+ T cells (36). 
CD122 
 
Β chain of IL2 
receptor 
Cell 
membrane 
Expressed by naïve CD4+CD25+Tregs 
(52) as well as CD8+ Treg (53), 
essential for in vivo development and 
maintenance of Tregs (54). 
 27 
Continued table 1.1 
Marker Full / other 
names 
Location Comments 
CD28  Cell 
membrane 
Naïve and activated Tregs (55), co-
stimulation via B7 (56). Important for 
anergic state (57), expression also 
seen on CD3+ and CD4+ T cells (36).  
CD45RB Protein tyrosine 
phosphatase 
(PTP) 
Cell 
membrane 
Involved in T cell activation,  
low on primed effector cells (58) and 
Tregs (59). Anti-CD45RB antibody 
prolongs allograft survival (60).  
CD62L  Cell 
membrane 
Expressed on 50-60% of naïve  
Tregs in mouse, not a marker of 
suppression activity (61), also 
expressed on CD25- T cell (24, 36). 
CD127 IL7Rα Cell 
membrane 
Low on Tregs, higher expression on 
most other CD4+ T cells (62), 
inversely correlates with FOXP3 
expression (63) 
FOXP3 Forkhead box 
P3 
 
 
 
Intranuclear Encodes for forkhead/winged helix  
transcription factor, important for 
Treg development and function (62, 
64), difficult for functional analysis 
due to intracellular location (65) 
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Recent evidence suggests that an adoptive transfer of in-vitro expanded 
Tregs can be used for therapeutic purposes in certain autoimmune disorders and 
to induce transplant tolerance (33, 66). In a murine model, the in-vitro expanded  
and adoptively transferred Tregs migrated preferentially to allograft and 
significantly delayed allograft rejection in the absence of immunosuppression 
(67). Another study on non-human primates documented potent suppressive 
activity of in-vitro expanded Tregs against allospecific xenogeneic stimulation 
(68). Somewhat similar observations have also been made during in-vitro 
experiments on peripherally expanded human Tregs (69, 70).   
In order to exert optimum homeostatic and inflammatory regulation, 
Tregs migrate to lymphoid or peripheral tissues including tumours, transplanted 
organs or other areas of inflammation (32, 71-73). A sound knowledge of the 
mechanisms controlling Treg migration in vivo is therefore crucial for their 
proper utilization in future cell based therapies. Tissue-specific Treg trafficking 
is dependent on a complex network of chemotactic signalling from cytokines, 
chemokines and adhesion molecules.  
1.4 Chemokines 
Chemokines are a superfamily of 8 to 11 kDa (67-127 amino acids) 
proteins with discreet roles in leucocyte activation, migration, haematopoiesis 
and angiogenesis (74-78). Because of their specificity, the chemokines direct 
selective leucocyte recruitment in response to inflammation, thus orchestrating 
the secretion of inflammatory mediators and tissue damage (79, 80). 
Chemokines are subdivided into four groups (C, CC, CXC, and CX3C) based on 
the position and separation of the first two amino-terminal cysteine residues of a 
four-cysteine motif in their primary amino acid sequence (81). There are two 
 29 
nomenclature systems for chemokines, the traditional abbreviations, such as 
interleukin (IL)-8 and monocyte chemoattractant protein (MCP)-1, and a 
systematic nomenclature that combines structural motifs (CXC, CC, XC, CX3C) 
with L for ligand and the number of the respective gene.  
Chemokines can also be divided into categories reflecting their temporal 
and spatial expression: the inducible (or inflammatory) and the constitutive (or 
homeostatic) chemokines (81-83). The inducible chemokines are promoted by 
pro-inflammatory stimuli such as tumour necrosis factor alpha (TNFα), 
interleukin-1 (IL-1), lipopolysaccharide (LPS) to control the recruitment of 
effector leukocytes in infection, inflammation, tissue injury, and tumours. Most 
inducible chemokines demonstrate broad target cell selectivity and act on cells 
of the innate as well as the adaptive immune system (84). The constitutive (or 
homeostatic) chemokines are produced at non-inflamed sites. They are important 
for immune surveillance, maintaining homeostatic leukocyte traffic and cell 
compartmentalization within lymphoid tissues, as well as homing of leukocyte 
precursors during haematopoiesis (81).  
1.5 Chemokine receptors 
All known chemokines bind to seven-pass, trans-membrane-spanning 
serpentine, Gi/Go protein-coupled, Bordetella pertussis toxin-sensitive receptors 
(75, 85). Chemokine receptors are designated according to the type of 
chemokine(s) they bind (CXC, CC, XC, and CX3C), followed by “R” (for 
receptor) and a number indicating the order of discovery. Binding of 
chemokines to the specific receptors triggers complex intracellular signalling 
cascades that rapidly promote the activation of leukocyte integrins and their 
adhesion to endothelial cells. This process leads to trafficking of immune cells in 
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response to adequate chemokine signals (86). Each chemokine family recruits 
only specific cell types, while the expression of receptors is further regulated 
according to the cell subsets, and/or the state of cell activation (87, 88). 
However, there is substantial redundancy in this system, with overlap in the 
ligand specificities, and some chemokines binding to multiple receptors (75).  
Approximately 50 chemokines and 20 chemokine receptors have been identified 
in humans (82). Some chemokine receptors form homodimers or heterodimers. 
This post-translational modification is suggested to add flexibility to the overall 
system, with formation of cell type- or activation-specific receptors (75, 80).  
1.6 Evidence for role of chemokines in acute rejection following cardiac 
transplantation 
Acute cellular rejection includes an infiltration of mononuclear cells into 
the allograft. Several studies in animal models have demonstrated an increased 
expression of CXC-chemokines (CXCL9, CXCL10 and CXCL11), associated 
with an infiltration of the corresponding receptor (CXCR3) expressing Th1 cells 
during rejection (89-91). Another study showed increased expression of 
CX3CL1 on rejecting allografts (92). Human studies showed variable patterns of 
the expression of CC and CXC-chemokines and chemokine receptors during 
acute allograft rejection (93-96). The expression levels increase in the later 
versus earlier rejections, despite no change in the grade of mononuclear infiltrate 
(97). The analysis of sequential human endomyocardial biopsies showed an 
association of CD3+ T-cell infiltration with the expression of CCR1, CCR3 and 
CXCR3. However, only CXCR3 and its ligand CXCL10 were up-regulated 
during acute rejection, suggesting a critical role for this chemokine pathway 
(93). (Table 1.2) 
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Table 1.2 Evidence for the involvement of chemokines in acute cardiac 
allograft rejection. All chemokines are mentioned according to the systematic 
nomenclature. The first column refers to the author and the year of publication. 
The table also shows whether the study was conducted in humans or other 
species. The final column shows the relevant conclusions from these studies. 
 
Study 
(ref) 
Chemokine Receptors Species Correlations 
Fairchild 
1997 
(91) 
 
 
 
CCL2 
CCL3, 
CCL4, 
CCL5,  
CXCL10, 
KC  
Not 
checked 
Mouse Increased gene expression of all 
chemokines in rejecting allografts; 
CXCL10 expression increased 
throughout rejection, while CCL3, 
CCL4 and CCL5 expression were 
high during late phase of rejection 
Hancock 
2000 
(89) 
CXCL9, 
CXCL10, 
CXCL11 
CXCR3 Mouse Intragraft mRNA expression of 
CXC chemokines correlate with 
rejection and infiltration of 
CXCR3+ mononuclear cells 
Robinson 
2000 (92) 
CX3CL CX3CR1 Mouse Increased CX3CL is associated 
with cellular infiltration and acute 
rejection 
Melter 
2001 (93) 
 
 
CCL2, 
CCL5, 
CCL11 
CXCL9, 
CCR1, 
CCR3, 
CCR5, 
CXCR3 
Human CCR1 strongly associated with T 
cell infiltration (p<0.001) but not 
with rejection 
CXCR3 strongly associated with 
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CXCL10, 
XCL1, 
CXCL12 
both T cell infiltration and 
rejection (p<0.001) 
Intragraft CXL10 and CCL5 
strongly correlated with acute 
rejection (p<0.05) 
 
Zhao 
2002 
(96) 
CXCL9, 
CXCL10, 
CXCL11 
CXCR3 Human Intragraft mRNA expression of 
CXCL9, CXCL10, and CXCR3 
correlated with acute rejection 
(p<0.05) 
Fahmy 
2003 
(94) 
 
 
CXCL8, 
CXCL9, 
CXCL10, 
CXCL11, 
CCL5, 
CCL2 
CXCR3, 
CCR5 
Human Intragraft mRNA expression of 
CXCL10, CXCL9, CXCL11, 
CCL5, CXCR3, and CCR5 
correlated with acute rejection 
(p<=0.009) 
Karason 
2006 (98) 
CXCL9 
CXCL10 
Not 
assessed 
Human 
 
Intragraft mRNA expression of 
CXCL9 correlated with acute 
rejection (p<0.05) 
Serum levels of chemokines 
showed no association with 
rejection 
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Further studies defined the cellular sources of chemokines during 
rejection. It is seen that the early expression (within 8 days following 
transplantation) of CXCL9 and CXCL10 in murine allograft are mediated by 
host CD8+ T cell, but not by CD4+ T cells or NK cells (99). Using human 
cardiac allograft biopsies, Zhao et al showed that CXCL10 and CXCL11 were 
expressed in vascular smooth muscle cells and CXCL11 in the endothelial cells, 
while infiltrating macrophages expressed CXCL9 as well as CXCL10 and 
CXCL11 (96). Another study showed that CXCL9 is produced by allograft 
endothelium, infiltrating macrophages and neutrophils (100). The precise 
pathways regulating differential secretion of these chemokines still remain 
elusive.  
A study using DNA microarray analysis showed that IFN-γ knockout 
mice rejected the cardiac allografts at the same pace as wild-type mice, with 
expression of a completely different set of chemokines and receptors genes 
(101). There was an up-regulation of CCL2, CCL3, CXCL12 and CXCR4 
despite the absence of IFNγ signalling. The sources of these chemokines were, 
however, not described. 
Morita et al investigated the role of sequential chemokine expression on 
trafficking of T cells into allografts during the progression of acute rejection in 
an animal model. They showed that the early chemokine cascade, including 
CCL2, CCL3, CCL4, CXCL1, CXCL10 and CX3CL1 are directed at the 
recruitment of the cellular component of the inflammatory system (i.e. 
neutrophils, macrophages, NK cells), which leads to a later upsurge of CCL5, 
CXCL9, CXCL10, CXCL11 causing recruitment of alloantigen primed T cells 
into the grafts (102).  
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Based on the observations that chemokines are involved in acute 
allograft rejection, investigations were carried out to determine if peripheral 
blood chemokine levels can be used as a marker of rejection. Karason et al 
compared the intra-graft gene expression of CXCL9 and CXCL10 with serum 
levels at the time of acute rejection in human heart transplant recipients. They 
concluded that acute rejection leads to a significant up-regulation of CXCL9 
mRNA in the graft, while the serum levels of both CXCL9 and CXCL10 remain 
unaltered (98).  
1.7. Evidence for role of chemokines in Cardiac allograft vasculopathy: 
Cardiac allograft vasculopathy (CAV), a hallmark of chronic rejection, is 
the leading cause of late death in heart transplant recipients (103). CAV results 
from a combination of complex pathological processes, including insults to the 
vascular integrity, immune response against the allograft, ischemia-reperfusion 
injury, viral infections, hypertension, hyperlipidemia, and diabetes mellitus 
(103). Acute rejection episodes are a critical risk factor for the subsequent 
development of chronic rejection (104, 105). There is evidence that allograft 
infiltration with activated T lymphocytes and macrophages precedes the 
development of intimal proliferation, the hallmark of CAV (106). In vivo data 
suggests that allogeneic T cells mediate graft endothelial cell dysfunction, 
followed by vascular smooth muscle cell dysfunction (107). Another interesting 
study suggested that the smooth muscle-like cells forming vascular neointima in 
the CAV are derived from circulating bone marrow-derived precursors (108).  
Similar to their well documented role in atherosclerosis (109), chemokines play 
a significant part in the development of CAV (table 1.3). Several animal studies 
have demonstrated that increased intra-graft expression of chemokines like 
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CCL2, CCL3, CCL4, CCL5, CXCL9 and CXCL10, along with corresponding 
receptors (CCR5, CCR2 and CXCR3), is associated with CAV (110-113). These 
results were complemented by chemokine-blocking studies; anti-CCL2 gene 
therapy in mice attenuated the development of CAV (114): blocking 
CCL5/CCR1 & CCR5 pathway with Met-RANTES reduced infiltration of 
CD4+, CD8+, and monocytes/macrophages into the allograft, and a subsequent 
attenuation of intimal thickening (115), and use of anti-CXCL9 antibody 
reduced T cell infiltration and intimal proliferation (112). Recent work on 
human cardiac allograft biopsies showed persistent elevation of CXCL10 and 
CXCL11 expression (but not CXCL9) in patients who developed significant 
CAV (96). Another study looking at peripheral blood levels of the CCR5 and 
CXCR3 ligands demonstrated that only CXCL11 levels were elevated in 
patients with CAV, while levels of CCL3, CCL4, CCL5, CXCL9 and CXCL10 
failed to show any correlation (116).  
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Table 1.3 Evidence for a role of chemokines in chronic cardiac allograft 
vasculopathy. All the chemokines are mentioned in the systematic 
nomenclature. The first column refers to the author and the year of publication, 
while the table also shows if the study was conducted in humans or any other 
species. The final column shows the relevant conclusions. 
 
Study 
(ref) 
Chemokines Receptors Species Correlations 
Pattison, JM 
1996 
(111) 
CCL5 Not 
checked 
Human Expression in mononuclear 
cells, myofibroblasts, and 
endothelial cells associated 
with CAV but not in normal 
coronary arteries 
Yun JJ 
2000 
CCL2, CCL5, 
CXCL1, 
CXCL10, 
XCL1 
Not 
checked 
Mice Late (day 4 onwards) and 
persistent intra-graft XCL1, 
CCL2 and CCL5 expressions 
were associated with 
macrophage and T cell 
infiltration and intimal 
proliferation 
Kao J 
2003 
(116) 
CCL3, CCL4, 
CCL5, 
CXCL9, 
CXCL10, 
CXCL11 
CCR5, 
CXCR3 
Human Elevated plasma levels of 
CXCL11 was associated with 
CAV (p<0.05); CXCL11 
localized to the endothelial 
surface of CAV lesions, 
associated with CXCR3+ 
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mononuclear cells infiltration 
Yun JJ 
2002 
(112) 
CXCL9 Not 
checked 
Mice Increased intragraft CXCL9 
levels increased significantly 
(p<0.001) by day 7 and 
remained elevated, preceding 
mononuclear cell infiltration 
and development of CAV. 
CXCL9 neutralization delays 
CAV 
Horiguchi 
2002 
(113) 
Multiple 
chemokines 
 
Multiple 
chemokin
e 
receptors 
Rats Enhanced intragraft 
expression of CCR2, CCR5, 
and CXCR3 genes with 
corresponding ligands in rats 
developing CAV (p<0.167)  
Van 
Loosdregt J 
2006 
(117) 
CXCL9, 
CXCL10, 
CXCL11, 
CCL5, 
CX3CL1 
CXCR3, 
CCR5, 
CX3CR1 
Human Intra-coronary expression of 
CXCL11, CCL5, CX3CL1, 
CCR5 and CX3CR1 were 
significantly elevated 
(p<0.05) in allograft with 
CAV as compared to those 
without 
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The inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase 
(commonly known as Statins) are the most common agents to treat 
hyperlipidemia frequently seen in transplant recipients. It has been well 
documented that statins can attenuate CAV (118). However, separate from a 
lipid altering mechanism of action, evidence also exists to suggest that statins 
have important immune-modulating properties. Pravastatin has been shown to 
inhibit monocytes CCL2 expression (119), while Yin et al demonstrated that 
simvastatin administration reduces the intra-graft levels of CCL2, CCL5 and 
CXCL10 with decreased expression  CCR2 and CCR5, and thus inhibited T cell 
and macrophage infiltration, with attenuation of CAV (120). Further evidence 
suggests that the anti-atherosclerotic potential of statins is independent of the 
type of statins or cholesterol-lowering properties. A study using pig-model of 
induced atherosclerosis compared the effects of Atorvastatin and Pravastatin 
versus placebo. The vascular expression of CCL2 was down regulated by 37% 
by both statins (p<0.05) compared to the placebo. This finding opens new 
insight into the pleiotropic effects of cholesterol lowering agents in heart 
transplant recipients. However currently, our knowledge remains limited about 
the mechanism of any potential immunoregulatory effects of statins within the 
atherosclerotic lesion.   
1.8 Chemokine pathways involved in Treg migration 
Several mechanistic studies have attempted to define pathways utilised 
for T cell trafficking during immune responses. Despite the apparent redundancy 
in the chemokine system, it appears that discreet chemokine pathways are 
responsible for migration of specific lymphocyte subsets (84). It is generally 
perceived that Tregs share the same chemokine receptor profiles as effector T 
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cells (73). However, evidence suggests that specific migration of Tregs in vivo is 
a result of differential expression of chemokine receptors, which might be 
different from the effector T cells. For example, effector T cells express CXC 
chemokine receptor, while its expression in Tregs is documented to be very low 
(37). Also, various organs can achieve different levels of Treg enrichment, 
which points to preferential expression of certain receptors in Treg population 
(121, 122). The following discussion emphasizes the importance of various 
chemokine pathways involved in Treg trafficking following transplantation. 
1.9 Lymphoid tissue homing chemokine pathway in transplantation 
1.9.1 CCR7 / CCL19, CCL21 pathway 
CCL19 (also known as macrophage inflammatory protein-3-beta) and 
CCL21 (also known as 6Ckine or the chemokine with 6 cysteines), the 
homeostatic chemokines constitutively expressed in the secondary lymphoid 
organs, are the only ligands for CCR7 (the CC-chemokine receptor 7) (123). The 
post capillary or high endothelial venules (HEV) of lymph nodes and Peyers 
patches constitutively express CCL21, while fibroblastic reticular cells within T 
cell zones of the lymph nodes express CCL21 as well as CCL19 (124). This 
pathway primarily controls movements of CCR7 expressing naïve and central-
memory T cells and Tregs through the secondary lymphoid tissue (SLT) in 
search of specific antigen, as well as trafficking of antigen-presenting dendritic 
cells from allograft to the SLT to initiate allospecific immune responses (125). 
Following organ transplantation, blood-borne circulation of dendritic cells to the 
draining lymph nodes is essential for tolerance induction (126). Subsequent 
signalling with CCL19 and CCL21 leads to T cell and DC co-localization in T 
cell areas, thereby facilitating antigen recognition and proliferation of T cells, 
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including Tregs that control the effector T cell response (127). CCR7 and its 
ligands are also essential for thymic development and central tolerance (128). 
Mice deficient in CCR7 or its ligands show disturbed lymphoid structure, 
impairment of central and peripheral tolerance, impaired Treg function, and 
develop autoimmune disorders (129). Menning et al demonstrated that more 
than 80% of murine naïve-like Tregs exhibit high CCR7 expression, while 
effector-memory like Tregs, albeit positive, show more heterogeneous 
expression. The also showed that CCR7 deficiency abolishes the lymph-node 
homing capacity of naïve-like Tregs; however, it favours accumulation of 
effector/memory-like Tregs  in the inflammatory areas, with enhanced 
suppression of inflammation (50). In humans, memory Tregs can be 
differentiated on the basis of differential expression of CCR7 into central 
memory (CCR7+) and effector memory (CCR7-) subsets (130). 
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Figure 1.2 T cell and antigen presenting cell (APC) trafficking in the 
secondary lymphoid tissue. The chemokines CCL19 and CCL21 cause T cell 
and APC migration from the high endothelial venules towards the T cell zone 
via the CCR7 receptor. Subsequent activation of the T cells via TCR (T cell 
receptor) stimulation leads to T cell proliferation and an up-regulation of various 
CC and CXC chemokine receptors, while causing a down-regulation of the 
CCR7 receptor. Tregs hence exert an inhibitory effect on the Teffector cells and 
the B cells (shown as red arrows). (Tcm = Central memory T cell, Tnaive = 
Naïve T cell, Treg = Regulatory T cell, Teffector = Effector cell) 
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Further evidence suggests that CCR7-related pathways may represent 
target of immunotherapy following transplantation. In a study using murine 
MHC mismatch kidney and cardiac transplantation, CCR7 pathways were 
blocked using recombinant CCL19-IgG1 (an agonistic chemokine fusion 
protein, produced to prolong the half life of CCL19 up to 24 hours). Prolonged, 
high dose stimulation by CCL19-IgG1 resulted in CCR7 downregulation, 
markedly reduced T cell and DC trafficking to the SLT, reduced allospecific 
effector T cell proliferation and prolonged allograft survival (from 9 days to 20 
weeks). However, this method failed to induce tolerance, since adoptive transfer 
of splenocytes from long term survivors (after 9 weeks) following CCL19-IgG 
treatment did not prevent rejection in untreated syngeneic mice (131). Another 
study using NOD.SCID mice showed via transfer that CD4+CD25+CD62L+ 
Tregs, high in CCR7 expression, were able to significantly delay the onset of 
diabetes when compared to CD4+CD25+CD62L- Treg, which were CCR7 
deficient, despite similar in vitro regulatory function (132). CCR7 expression 
has been implicated in tumour survival and progression for various cancers (133, 
134), and blocking CCR7 via monoclonal antibodies and chemotherapy has 
shown promising results in experimental cancer therapies (135).   
1.9.2  CXCR5/CXCL13 pathway and Tregs 
CXCL13, also known as BCA-1 (B-cell attracting chemokine 1), is a 
primary B cell chemoattractant (136), secreted by germinal centre T helper cells 
(GC-Th) and follicular dendritic cells (137). It plays a major role in the humoral 
arm of alloresponse or autoimmunity (138). 
While only a small subset of CD4+CD25+Tregs naturally express 
CXCR5 (approximately 10-30%), the expression appears significantly enhanced 
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following TCR stimulation. Hence, after activation in the T cell zone, Tregs 
acquire the ability to migrate to the B cell area, where they suppress B cell 
survival, immunoglobulin synthesis, and activation-induced cytidine deaminase 
(AID) expression (139). Hence, this chemokine pathway is critical in the 
regulation of adaptive humoral immune response. In a study using an MHC-I 
mismatched rat transplant model, Tregs activated by the indirect pathway 
prevented alloantibody mediated rejection (140). Further studies are warranted 
in this area to explore the possibilities of using the CXCR5/CXCL13 pathway 
for inducing transplant tolerance. 
1.10 Peripheral tissue homing chemokine pathways in transplantation 
1.10.1 CCR4 / CCL17, CCL22 and CCR8 / CCL1 pathways 
Antigen priming in SLT causes an overhaul of chemokine receptors on 
Tregs, from CCR7 and CXCR5 to effector-memory-like chemokine receptors 
including CCR2, CCR4, CCR6, CCR8 and CCR9 (141). This heterogeneous 
expression of homing receptors enables Tregs to migrate to different non-
lymphoid organs (142).   
In a study comparing chemotactic profile of human peripheral blood 
Tregs against their CD25- counterparts, Tregs showed greater selective 
expression of CCR8 (p=0.0001) and CCR4 (p=0.03) than CD4+CD25- cells. In-
vitro chemotaxis assays also demonstrated a significantly greater (p <0.01) 
migration of Tregs compared to CD25- T cells in response to the CCR4 ligands, 
CCL17, CCL22, and CCR8 ligand, CCL1, plus a synergistic effect of the 
suboptimal doses of CCL1 and CCL22 (37).  
In a murine model of induced allo-tolerance via CD154mAb and donor 
specific transfusion (DST), tolerance was associated with up-regulation of 
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CCL22 and CCR4 and infiltration of Tregs in the allograft. CCR4-/- mice 
rejected the allograft associated with reduced infiltration of Tregs, however, the 
number and function of peripheral Tregs were normal. The study demonstrated 
that CCL22/CCR4 axis does not impact on Tregs development, but plays a key 
role in Tregs migration to the allograft. The authors failed to find any 
association with CCL17 expression and Tregs allograft infiltration (143). 
However, another study using fully mismatch murine cardiac transplant model 
with induced tolerance showed that alloantigen-bearing plasmacytoid DC 
migrated to lymph nodes and affected allospecific Treg development via the 
CCR4/CCL17 pathway. The same protocol in CCR4-/- mice prevented failure of 
Treg development, leading to rejection (144).  
CCR4 and CCR8 are also expressed and used by effector T cells (145, 
146) and skin homing (but not gut homing) memory T cells, therefore fine 
spatial and temporal balancing operates in vivo for self tolerance and during an 
alloresponse (147). In the study by Lee et al (143), CCR8 expression was higher 
in rejecting allografts, which could be due to infiltration of either the effector T 
cells or Tregs in response to inflammation. They showed that the CCR8 / CCL1 
pathway is not critical for immune tolerance, at least in their model, since CCL1 
blockade did not affect tolerance induction. Much still needs to be learnt about 
the precise in vivo role of these pathways for Tregs trafficking.  
1.10.2 CXCR3 / CXCL9, CXCL10, CXCL11 pathways 
Th1-associated CXC chemokines, CXCL9 (monokine induced by 
gamma-Interferon) CXCL10 (Interferon-inducible protein-10) and CXCL11 
(Interferon-inducible T-cell alpha chemoattractant) have often been associated 
with acute allograft rejection (89, 90), but it is uncertain if they play a role in 
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Tregs trafficking. Under homeostatic conditions Tregs express low levels of 
CXCR3, and show minimal chemotactic response to the three inflammatory 
CXC chemokines (37). The expression probably increases during the stress 
response of inflammation or rejection following transplantation. Eksteen et al 
demonstrated the presence of CXCR3high Tregs around inflamed bile ducts in 
chronically inflamed human liver (72). A study on kidney allografts in primates 
demonstrated a significant correlation between rejection and infiltration of the 
grafts with Tregs (148). In a murine model of experimental autoimmune 
encephalomyelitis, CXCR3 expression was associated with infiltration of Tregs 
and containment of the tissue damage (149).  
Hence, it is likely that the CXCR3 axis is involved in Treg homing to the 
allograft at the time of acute rejection. Hasegawa and colleagues utilized this 
pathway by developing an in vitro expanded, transfected Treg variant expressing 
high levels of CXCR3. Following adoptive transfer in a GVHD-model of 
B6D2F1 mice, these Tregs localized to the target organs and suppressed the 
GVHD in a dose-dependent manner (150). 
1.10.3 Bone marrow homing chemokine pathway 
Bone marrow is a part of the lymphocyte recirculation network and 
particularly enriched in functional CD4+CD25+FOXP3+ Tregs (141, 151). Zhou 
et al demonstrated that human Tregs preferentially migrate to bone marrow 
using CXCR4 / CXCL12 axis, express more FOXP3 and were more suppressive 
than blood-borne Tregs (121). It is likely that Treg mobilization explains the 
amelioration of acute GVHD (graft-versus-host disease) by GCSF (granulocyte 
colony stimulation factor) treated blood mononuclear cell transplantation, since 
GCSF mobilizes bone Tregs by decreasing marrow CXCL12 levels (121, 152). 
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A similar mechanism of action may account for another study that showed 
reduction in the severity of murine experimental allergic encephalomyelitis by 
GCSF (153).  
In a fully mismatched rat cardiac allograft model, GSCF injections 
following transplantation led to enhanced Treg population in the peripheral 
blood and prolonged allograft survival. By determining ratios of Tregs to the 
CD4 cell population in bone marrow and spleen, the authors established that 
Tregs were mobilized from the bone marrow (154). However, the prophylactic 
use of GCSF to prevent rejection in the early postoperative period in a 
randomized, placebo-controlled, double-blind, multicenter trial following human 
liver transplantation failed to show any benefits (155). This could probably be 
due to a difference in species, or the simultaneous mobilization of effector T cell 
populations from the bone marrow.  
Hence in order to utilize bone marrow Tregs for the induction of 
tolerance, there is a need for such agents that can preferentially target CXCR4 
on Tregs, without affecting the effector T cells. Recently, some CXCR4 
antagonists have been used in non-transplant experimental studies with 
promising results; TN14003 has shown to block CXCL12-induced migration 
and invasion of pancreatic tumour cells (156), AMD3100 reduced airway 
inflammation and hyper-reactivity in a mouse model of asthma (157), the same 
compound also suppressed the severity of murine collagen induced arthritis 
(158), CTCE-9908 inhibited migration and division of osteosarcoma cells in 
vitro and decreased pulmonary metastases in a murine model (159). These 
developments suggest other possible means for mobilizing Tregs from bone 
marrow for therapeutic applications. 
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Figure 1.3 Diagram showing chemokine pathways involved in the Treg 
migration between various organs. Naïve Treg (before activation by antigen 
stimulation), are CCR7+CCR9low and migrate to the Secondary Lymphoid tissue 
in response to CCL19 and CCL21. Here, stimulation by an antigen presenting 
cell leads to an up-regulation of various CC and CXC receptors, and a down-
regulation of CCR7. This change of receptor profile enables the Treg to migrate 
towards other organs, such as the allograft, the skin, mucosal epithelium, and the 
bone. The various chemokines affecting this migration are shown with arrows.  
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1.10.4 CCR10 / CCL28 pathway 
CCR10 is expressed on T and B cell subsets that constitutively migrate 
to gastrointestinal and non-intestinal mucosal epithelial sites (such as liver) via 
CCL28 (also known as MEC or mammary enriched chemokine) (160). Liver is 
considered a tolerogenic organ, where Tregs mediate allograft acceptance across 
MHC-barriers (161). It is likely that Tregs also use the CCL28 / CCR10 
pathway for migrating to liver allografts during tolerance induction; however, 
there is a paucity of supporting data. A study of chemotactic signals for Tregs 
during chronic hepatic inflammation in humans reported a 25-fold up-regulation 
of CCL28 in biliary and portal epithelium, associated with the infiltration of 
functional CCR10+ CXCR3+ Treg (72). Using a rat model of liver transplant 
rejection (DA-LEW), Pu et al showed that adoptive transfer of alloantigen 
stimulated Tregs prolonged allograft survival (30 vs. 12 days in control group). 
Surprisingly, a short course of tacrolimus gave an even better outcome (more 
than 60 days) (162). The authors failed to explain the unexpected synergistic 
effect between tacrolimus and Tregs, since tacrolimus has been reported to 
impair Treg expansion (163). Also, they did not mention migratory pathways 
responsible for Treg trafficking to the liver allografts.  
1.10.5 CCR5 / CCL5, CCL4 pathways: 
Expression of the chemokine receptor CCR5 has been associated with 
pro-inflammatory cellular infiltration in acute and chronic allograft rejection 
(102, 164, 165), tumours (166), and inflammatory conditions (167). Its ligands 
include CCL5 (RANTES or regulated upon activation, normal T-cell expressed, 
and presumably secreted), CCL3 (MIP-1-α or macrophage inflammatory 
protein-1-alpha) and CCL4 (MIP-1-β or macrophage inflammatory protein-1-
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beta). The role of CCR5-related pathways in Treg migration following organ 
transplantation remains elusive. A study on mice showed that approximately 
20% of Tregs in murine SLT constitutively express CCR5 and immune 
activation leads to enhanced expression of both CCR5 and Foxp3. The same 
study revealed that CCR5/CCL4 pathway caused preferential accumulation of 
Tregs in the gravid uterus for tolerance induction (168). Further evidence 
suggests that Tregs up regulate CCR5 expression in certain pathological states 
for peripheral migration. In chronic inflamed intestine of SAMP/Yit mice, the 
CCR5 / CCL5 pathway was preferentially used by Foxp3+ Tregs for homing to 
the inflamed tissues. Interestingly, activated CD8+ T cells were the major source 
of the secreted CCL5, suggesting a possible role of CCL5 in balancing the 
effector and regulatory response. It was demonstrated that in vitro activation 
caused significantly more Foxp3+ cells than Foxp3- cells to express CCR5, and 
their migration was blocked by TAK-779, a CCR5 antagonist (169). In murine 
pulmonary mycosis, Tregs showed enhanced expression of CCR5 compared to 
effector T cells and migrated to the fungal lesions, with subsequent dampening 
of the immune response against the disease (170). Another study in murine 
model of acute GVHD reported that Tregs used CCR5-related pathways for 
homing to the target organs, and this migration was essential for suppression of 
the effector response. The investigators did not mention the chemokines 
involved in this migration (171). Taken together, these observations suggest that 
CCR5-related pathways play a significant role in tolerance induction following 
organ transplantation. 
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1.11 Do immunosuppressants modulate chemokine receptors on Tregs? 
The effects of various immunosuppressant agents on the proliferation 
and suppressive capability of Tregs has been well documented (163). However, 
little is known about the effects of these interventions on chemokine receptor 
profile of Tregs. It is well known that immunosuppressive agents such as 
cyclosporine alter the chemokine receptor expression and migratory capacity of 
dendritic cells (172). It is likely that Tregs also switch chemokine receptors and 
homing potentials in response to therapeutic interventions. Knowledge of such 
effect can provide an opportunity to alter therapy for tolerance induction 
following transplantation.  
Summary: 
Treg cells are a heterogeneous group of lymphocytes with potent 
immunosuppressive capacity. These cells use different chemokine pathways for 
tissue selective migration, depending on the pathophysiological mechanism. The 
relevance of various chemokine networks in Tregs migration in the transplant 
scenario is still elusive. Further knowledge in this area is required to help in 
designing cell-based immunotherapy, particularly to induce transplant tolerance.  
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Chapter 2 Materials and methods 
2.1 Study Subjects 
This part prospective, part retrospective observational, non-randomized, 
cross-sectional study included adult heart transplant recipients under routine 
follow up at the University Hospital of South Manchester NHS Foundation Trust 
(UHSM). The study was approved by the local research ethics committee and 
group informed consent was obtained from all the participants. All the biological 
samples were collected and stored in accordance with the Human Tissue Act 
2004. The study was carried out in conformation with the spirit and the letter of 
the declaration of Helsinki, and in accord with the ICH Good Clinical Practice 
Guidelines. 
2.2 Blood samples 
A 5 ml peripheral blood sample was collected from research participants 
in an EDTA (ethylenediamine-tetra-acetic acid) vacutainer, using standard 
venepuncture technique. The samples were then either used to separate plasma 
via centrifuge, or used for isolation of peripheral blood mononuclear cells, 
depending on the experiments. 
2.3 Luminex immunoassay 
Plasma concentrations of chemokines were measured using multiplex 
bead-based Luminex® technology (Invitrogen, UK). The Multiplex technology 
incorporates solid phase immunoassays using spectrally encoded antibody-
conjugated beads as the solid support. The assay is performed in a 96-well plate 
and analyzed with a Luminex® 100™ instrument, capable of simultaneous, 
precise in-vitro quantitative analysis of up to 100 different proteins in a single 
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well (also called xMAP technology). The use of xMAP technology for bioassays 
is now well described (fig 4). 
In short, the technology used 5.6µm polystyrene beads, called 
microspheres, internally dyed with red and infrared fluorophores of different 
intensities and given unique numbers, allowing differentiation of one bead from 
another (fig 4a). Each bead set is conjugated with capture antibody for a specific 
bioassay, and added along with samples (including standards, control and test 
sample) into the wells of the filter bottom microplate. The plate is then 
incubated for 2 hours, when capture antibodies bind to the specific proteins 
(analyte) (fig 4b). After washing the beads, protein-specific biotinylated detector 
antibodies are added and incubated for another hour, when biotinylated 
antibodies bind to the specific immobilized proteins (fig 4c). After washing 
excess biotinylated antibodies, streptavidin conjugated to fluorescent protein, R-
Phycoerythrin (Streptavidin-RPE) is added and the plate incubated for another 
30 minutes. The Streptavidin-RPE binds to the detector antibodies, thus forming 
a four-member solid phase sandwich, to be analyzed by the Luminex system (fig 
4d). By detecting the spectral properties of capture beads and measuring the 
amount of associated RPE fluorescence, the concentration of one or more 
proteins is determined. 
I used Human Thirty-Plex Antibody bead kit (Invitrogen®, CA) for 
measuring the peripheral blood chemokine levels. This bead kit comprises 
analyte specific components for the measurement of several human cytokines 
and chemokines. For the purpose of this specific experiment, I measured 
chemokines only. I am aware that the antibody bead kit is mostly used with the 
serum or the tissue culture medium samples; however, it can be used with 
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plasma, with satisfactory sensitivity and minimum interassay variation. For the 
selected chemokines, the assay sensitivity is between 5-15 pg/ml, with an 
interassay variation between 2.9 to 6.9%.  
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Figure 2.1 Diagrammatic representation of the Multiplex bead-based 
Luminex® Assay. Fig 2.1(a) shows the first step when the antibody-conjugated 
beads are added to the well. Fig 2.1(b) shows the analyte capture by the specific 
antibody when added to the wells with the specific antibody-conjugated beads. 
Fig 2.1(c) represents the third step when the biotinylated detector antibody binds 
to the analyte-antibody complex, creating a sandwich. Fig 2.1(d) shows the 
analyte detection by the fluorescence of the Streptavidine-RPE bound to the 
detector antibody. (RPE = R Phycoerythrin)   
 
   
 
 
 
   
 
Fig 2.1(a)  Fig 2.1(b) 
Fig 2.1(c) Fig 2.1(d) 
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2.4 Isolation of Peripheral Blood Mononuclear Cells (PBMC) for flow 
cytometry 
A peripheral blood sample collected in an EDTA vacutainer was used to 
isolate PBMC by density gradient centrifugation method using Ficoll-Paque as 
previously described (173). The blood is processed within 1-3 hours of 
collection under aseptic conditions. The blood is diluted 1:1 with room 
temperature standard RPMI-1640 (Sigma-Aldrich®, MO) in a polypropylene 
universal container and gently mixed. Eight ml of blood and RPMI mixture is 
then carefully layered over seven ml of Ficoll-Paque cushion in a polypropylene 
centrifuge tube, followed by centrifuge at 3000 rpm for 30 min. The PBMC 
layer is then carefully withdrawn with a pipette, and transferred to another 15 ml 
centrifuge tube. The cells are then washed in room-temperature phosphate 
buffered solution (PBS) and centrifuged at 1500 rpm for 15 minutes. The 
supernatant is aspirated, and the cells resuspended in room-temperature RPMI-
1640, to achieve a viable cell density of 1-1.25 x 106 cells/ml. The cells are 
counted using Neuber cell counter.  
2.5 Chemokines for Chemotaxis assays 
The following recombinant human chemokines were used for in-vitro 
chemotaxis assays; CCL1 (T lymphocyte-secreted protein I-309), CCL2 
(Monocyte Chemotactic Protein-1 or MCP-1), CCL5 (Regulated upon 
Activation, Normal T-cell Expressed, and Secreted or RANTES), CCL17 
(Thymus and Activation Regulated Chemokine or TARC), CCL19 (Macrophage 
Inflammatory protein-3 beta or MIP-3β), CCL21 (6Ckine, Secondary 
Lymphoid-Tissue Chemokine, or SCL), CXCL9 (Monokine induced by gamma-
interferon or MIG), and CXCL10 (Interferon-gamma-induced protein or IP-10) 
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(purchased from ProSpec-Tany TechnoGene Ltd, Israel). A stock solution of 
each chemokine is made according to manufacturers’ guidelines. It is further 
diluted according to the required strength for chemotaxis, and aliquots were 
stored to avoid repeat freeze-thaw cycles. A carrier protein (0.1% bovine serum 
albumin) was added for long term storage.  
2.6 Chemotaxis assay 
The use of in-vitro cell migration assays across a barrier membrane with 
pores of a known size and density has been well documented (89, 174, 175). I 
utilized 24 well insert system purchased from BD Falcon™. It is a cell culture 
insert assays platform composed of a multiwall insert plate with a microporous 
PET (Polyethylene Terephthalate) membrane, a 24-well assay plate, or feeder 
tray and lid. The 24 wells are integrated into a one-piece plate, making it easy to 
move the insert if necessary. All the inserts are handled under aseptic conditions. 
250µl of the cell suspension is added to the insert, while 750µl of chemokine 
solution in RPMI-1640 is added to the lower well in order to neutralize the 
effects of hydrodstatic pressure across the membrane according to the 
manufacturer’s guidelines. A negative control is used for each patient, using 
750µl of RPMI without chemokine in the lower well. The system is left 
incubated for 4 hours in 37oC, 5% CO2 and normal humidity. Following 
incubation, transfer of Treg to the lower chamber was assessed using flow 
cytometry.  
2.7 Flow Cytometry 
I used BD™ LSR II flow cytometer for Treg-immunophenotyping. BD 
LSR II is an air-cooled, multi-laser, bench top flow cytometer with the ability to 
acquire parameters for a large number of colours. It uses fixed-alignment lasers 
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that transmit light reflected by mirrors through a flow cell to user-configurable 
octagon and trigon detector arrays. The octagon is an array of photomultiplier 
tubes (PMTs) and filters that can detect up to eight signals, while trigon can 
detect up to three signals. These detectors collect and translate fluorescence 
signals into electronic signals. Instrument electronics convert these signals into 
digital data. 
The BD LSR II has a fixed-alignment 488-nm blue laser (Coherent 
Sapphire) with the option of additional fixed-alignment lasers to analyze a 
stream of fluid containing individual cells. The primary blue laser generates 
forward scatter (FSC) and side scatter (SSC) signals and four fluorescence 
signals. The optional red (633-nm laser), violet (405-nm) and UV (355-nm) 
lasers generate two fluorescence signals each. There are dichroic optical filters, 
which transmit light of a specific wavelength, while reflecting other 
wavelengths. Light signals are generated as particles pass through the laser beam 
in a fluid stream. When these optical signals reach a detector, electrical pulses 
are created that are then processed by the electronics system. 
The flow cytometry requires optimum alignment of the optical and 
fluidics system to maximize the detection of fluorescence and ensure optimal 
sensitivity and resolution for forward scatter (FSc) and side scatter (SSc) signals. 
Hence frequent checks were made to ensure optical alignment was optimised 
and compensation was corrected for spectral overlap. The use of uniform 
fluorospheres for optical alignment verification has been well established (176). 
We used BD™ Cytometer Setup and Tracking beads, which consists of equal 
concentrations of 3-µm bright, 3-µm mid, and 2-µm dim polystyrene beads in 
PBS with bovine serum albumin (BSA), and sodium azide in a stream-tip 
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dropper vial. The beads are dyed with a mixture of fluorochromes that are 
excited by the lasers used in BD digital flow cytometer. Median fluorescence 
intensity (MFI) and percent robust CV (% rCV) are measure for each bead 
intensity in all fluorescence detectors. Software algorithms differentiate the 
fluorescence signals from each bead type based on size and fluorescence 
intensity in each detector, Linearity, detector efficiency (Qr), optical background 
(Br), electronic noise and laser delays are all evaluated, PMT voltages are then 
adjusted to maximize population resolution in each detector, hence providing 
better resolution of dim populations, fewer compensations artefacts, and 
reproducible data.  
2.8 Treg immunophenotyping 
A 100µl of the specimen from a suspension of PBMC or cell suspension 
from the lower well in the HTS multiwall system was extracted into each 
analysis tube (5ml polypropylene FACS tube). Treg cells were labelled with the 
following directly conjugated antibodies: 1. Phycoerythrin-Cy5 (PE-Cy5) 
conjugated anti-CD4, 2. Phycoerythrin-Cy7 (PE-Cy7) conjugated anti-CD25 
(BD Biosciences, UK), for 30 minutes in the dark at 4oC (to avoid denaturing by 
UV light). Staining with fluorescein isothiocyanate (FITC)-conjugated anti-
human FOXP3 (e-Bioscience, UK) was performed with 
fixation/permeabilization solutions according to the manufacturer’s guidelines. 
In short, following incubation with anti-CD4 and anti-CD25 antibodies, the 
sample was washed once with 1 ml of PBS and centrifuged at 1500 RPM for 10 
min. The cell pellet was resuspended with pulse vortex and 1 ml of freshly 
prepared Fixation/Permeabilization buffer solution was added to each sample 
and incubated at 4oC for 45 min in the dark. The  sample was then washed once 
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with 2 ml of 1x permeabilization wash buffer (freshly made from 10x 
permeabilization buffer) followed by centrifugation at 1500 RPM for 10 min and 
gentle decanting of the  supernatant. The cell pellet was once again suspended 
with pulse vortex, and stained with FoxP3 FITC antibody at 4oC for 45 min in 
the dark. The sample was then washed twice with 2 ml of 1x permeabilization 
buffer, centrifuged at 1500 RPM for 10 min and resuspend in 100µl of PBS 
before analyzing in the flow cytometer.  
2.9 Isotype Controls 
A further 100µl of PBMC were stained with combinations of mouse 
IGg1-PCy5, PCy7, and FITC as isotype control, Isotype controls were included 
in all experiments, to provide a negative cell reference and also to set up 
regional quadrants on scatter plot graphs for assessing cell populations (Figure 
2.2 – 2.4). 
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Figure 2.2 Dual scatter histogram from an isotype control 
This demonstrates an absence of positive fluorescence staining within the gated 
area (shown by an assigned green colour). 
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Figure 2.3 Scatter plot from isotype control 
 
This represents a scatter plot constructed from the gated area in figure 2.1. 
Quadrants have been assigned to determine the ‘positively’ controlled areas 
from the isotype control (seen in quadrant F3). 
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Figure 2.4 Histogram from isotype control. This is a histogram which 
confirms a control staining area and the absence of positive staining (no activity 
within area B) 
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2.10 Gating Strategy 
BD FACSDiva™ software was used to create gating strategy protocols. The 
following protocol was established for analysis of a given sample: 
• A forward scatter - side scatter (FSc:SSc) plot was first produced (Figure 
2.5). This enabled simple visualisation and differentiation of lymphocytes 
according to cell size and granularity. A manual gate (labelled Gate P1, red) 
was then created around the lymphocyte region on the FSc:SSc histogram 
(Figure 2.5). Further data analysis and collection was then only performed 
on cells in this region.  
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Figure 2.5 Scatter plot showing lymphocyte gating strategy. A 
representative scatter plot showing a manual gate (P1) created around the 
lymphocyte region. Further analysis was performed on the cells within the 
lymphocyte gate only.   
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• In the next step, a forward scatter - side scatter (FSc:SSc) were produced for 
each colour / antibody, using the cells from the previously gated 
lymphocytes. Fluorescence outside of the gating regions is considered non-
specific (isotype control). To enhance visualisation of cell populations in the 
FSc:SSc plot or a histogram, each positive antibody gate was assigned a 
colour (Fig 2.6-2.8).  
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Figure 2.6 Gating strategies for CD4 (green) on a scatter plot. A 
representative scatter plot showing the gating strategy for visualizing CD4+ cells 
(green). The cells outside the gate are the lymphocytes that are CD4- (red).  
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Figure 2.7 Histogram showing CD25 staining. A representative histogram 
with staining area (P1) in CD25 zone, and an absence of staining outside P1 
(control).  
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Figure 2.8 Histogram for FOXP3 staining. A representative histogram 
showing positive staining for FOXP3 within the blue zone, and an absence of 
staining in the adjacent area (FOXP3-).  
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• In the third step, a further gating strategy was defined to identify those 
cells which are positive for both CD4 and CD25 staining. Hence, another 
FS:SS plot was created for CD4 and CD25, using cells from the CD4 
positive cells only. Another gate was placed to identify CD4+CD25bright 
cells (shaded green in Fig 2.9) 
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Figure 2.9 Gating strategies for CD4+CD25bright cells. A representative 
scatter plot showing dual staining for CD4 and CD25. A further gate was created 
on the cells staining most brightly for the CD25 (CD4+25bright, green cells within 
the quadrant Q2-1).  
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• Finally, further scatter plot was created to identify CD4+CD25bright cells 
staining positive for FOXP3, as shown in figure 2.10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 72 
 
 
 
Figure 2.10 Scatter plot with gating strategy for Treg. A representative  
scatter plot showing CD4+CD25brightFOXP3+ (Tregs), within the quadrant Q2-3. 
Quadrant Q1-3 shows CD4+CD25- cells which are also FOXP3-.   
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2.11 Immunofluorescence staining 
I used immunofluorescent detection technique to co-localize Treg 
markers with the chemokine in formalin-fixed, paraffin-embedded (FFPE) 
endomyocardial biopsy tissue from stable and rejecting adult heart transplant 
recipients. In this method various target antigens are first labelled with primary 
antibodies, which are then detected by fluorochrome-conjugated secondary 
antibodies using immunofluorescence scanning microscopy (177, 178).  The 
primary antibodies and the secondary, fluorochrome-conjugated secondary 
antibodies are listed in tables 2.1 and 2.2. 
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Table 2.1 Primary antibodies used for Immunofluorescence staining in 
the formalin-fixed, paraffin-embedded endomyocardial biopsy tissue.  
 
 
Antigen Isotype / clone, catalogue number Supplier 
CD4 Mouse IgG1 
clone BC/1F6, # ab846  
Abcam®, Cambridge, UK 
FOXP3 Rat IgG2a, κ,  
clone PCH101, #  14-4776 
ebioscience®, CA 
CCL17 Goat polyclonal, # AF364 R&D systems, 
Minneapolis, MN 
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Table 2.2 Secondary antibodies used for Immunofluorescence staining 
in the formalin-fixed, paraffin-embedded endomyocardial biopsy tissue.  
 
 
 
Antigen Isotype / clone, 
catalogue number 
Supplier 
Alexa Fluor® 488 donkey 
anti-rat IgG (H+L) 
Cat no A-21208 Invitrogen®, UK 
Alexa Fluor® 555 donkey 
anti-mouse IgG (H+L) 
Cat no A-31570 Invitrogen®, UK 
Alexa Fluor® 647 donkey 
anti-goat IgG (H+L) 
Cat no A-21447 Invitrogen®, UK 
 
DAPI (4',6-diamidino-2-phenylindole dilactate) was used to counter stain nuclei. 
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The FFPE samples of the endomyocardial biopsies were collected from 
the archives of the UHSM Pathology department following informed consent. 
The endomyocardial biopsies are routinely used to diagnose rejection following 
hear transplantation (179). The procedure is usually performed via the right 
internal jugular vein route or the right common femoral vein route. All tissue 
samples are routinely fixed in 4% buffered formalin and subsequently embedded 
in paraffin blocks by conventional techniques. For the diagnosis of rejection, the 
biopsy samples are stained with haematoxylin and eosin, and then analyzed by 
experienced histopathologists at the Department of Pathology at UHSM. The 
biopsies are graded between 0-3R according to the recent International Society 
of Heart and Lung Transplantation (ISHLT) grading system (180). 
2.11.1 Tissue slide preparation 
From the FFPE tissue blocks, 3-4 µm thick tissue slices were cut using 
standard microtome. The tissue sections were then floated onto a warm (42°C) 
water bath from where they are picked up onto X-Tra® adhesive slides 
(Surgipath®, UK). These slides are made using a special process to produce a 
permanent positive (+) charged surface which helps to bond tissue sections and 
cytology preparations without the use of additional adhesives. Once mounted, 
the slides were left to dry overnight at room temperature, followed by incubation 
at 60ºC for 30 minutes to help the section adhere to the slide. 
2.11.2 Dewaxing and Antigen retrieval 
Formalin or other aldehyde fixation forms protein cross-links that mask 
the antigenic sites in tissue specimens, thereby giving weak or false negative 
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staining for immunohistochemical detection of certain proteins. Hence, antigen 
retrieval is performed in order to facilitate epitope unmasking. Antigen retrieval 
can be performed by heat-induced (also known as heat-induced epitope retrieval 
or HIER) or enzymatic methods. HIER can be performed using Citrate buffer 
(pH 6.0) or Tris/EDTA buffer (pH 9.0), in a pressure cooker, microwave oven, 
or a water bath. The buffer solution is designed to break the protein cross-links, 
therefore unmasking the epitopes in FFPE tissue sections. During optimization 
experiments for individual antibodies, I tested HIER with both buffers in 
different heating condition, as well as enzymatic retrieval with pepsin.   
Prior to antigen retrieval, the tissues were deparaffinised using four 10 minute 
washes in 100% xylene, agitating for 10 sec every 30 sec. This was followed by 
rehydration in graded ethanol solutions (100%, 90%, 75%, and 50%) for 3 
minutes each, agitating every 20 sec, before rinsing in water.  
In the first step, antigen retrieval was performed using pre-warmed 
buffer in a water bath (warmed to 90ºC). The slides were left in the water bath 
for 30 minutes, followed by 20 minutes on the bench at room temperature for 
cooling, and then 10 minutes under running water. However, I found inadequate 
staining of the various antibodies using this technique. 
Subsequently, I used pressure cooker with Citrate buffer or Tris/EDTA buffer 
for HIER with optimum results for CD4 and FOXP3 antibodies.  
In order to make sure that the sections are never dry, all staining 
procedures were carried out in a humidified chamber. I used a shallow plastic 
box with a sealed lid and wet tissue paper in the bottom as our incubation 
chamber. The plastic serological pipettes were cut into lengths and glued at the 
bottom of the chamber, with the 2 individual pipette tubes of each pair being 
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placed about 4.0 cm apart. It helped to keep slides off the paper and be laid flat 
so that the reagents don’t drain off. 
2.11.3 Blocking Step 
In order to minimise background or un-specific staining, I used 5-10% 
normal horse serum (serum from the host of the secondary antibodies), prepared 
by diluting normal horse serum in PBS. The slides were removed from water, 
gently wiped around the section and then 200µl PBS was carefully added to 
prevent the section from drying out. Dako pen (Dako®, DK) was used to ring the 
island, in order to provide a barrier to liquids applied to the sections. This was 
followed by gently pipetting 200µl of 10% blocking serum on to the section 
before placing the slide in a moist chamber at room chamber for 30 minutes. The 
slides were then rinsed again in PBS before staining with the primary antibodies. 
2.11.4 Immunofluorescence staining for CD4 and FOXP3 
To determine optimum staining concentrations for each antibody, 
different antigen retrieval techniques and dilutions were tested according to the 
manufacturers’ recommendations and published guidelines, along with positive 
and negative controls. For positive controls, anonymous archival tonsil tissues 
were obtained from the department of Pathology at UHSM, while the primary 
antibodies were omitted to create negative controls. 
Table 2.3 summarizes the best antigen retrieval method and dilutions for 
CD4 and FOXP3 antibodies, and their corresponding secondary antibodies. 
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Table 2.3 Antigen retrieval and staining protocol for CD4 and FOXP3 
in the formalin-fixed, paraffin-embedded human endomyocardial biopsy 
tissue. The method was optimized for mouse antihuman CD4 (clone BC/1F6) 
and rat anti-human FOXP3 (clone PCh-101). (HIER = Heat Induced Antigen 
Retrieval, PBS = Phosphate Buffered Saline).  
 
 Mouse anti-human 
CD4 (BC/1F6) 
Rat anti-human 
FOXP3 (PCH-101) 
Antigen retrieval HIER HIER 
Buffer Citrate buffer (pH 6.0) Citrate buffer (pH 6.0) 
Heating method Pressure cooker, 4 
minutes on full pressure 
Pressure cooker, 4 
minutes on full pressure 
Dilution of the primary 
antibody 
1:50 (2% blocking serum 
in PBS) 
1:50 (2% blocking serum 
in PBS) 
Staining time and 
temperature 
Overnight 4ºC Overnight 4ºC 
Secondary antibody Alexa Fluor® 555 
donkey anti-mouse IgG 
(H+L) 
Alexa Fluor® 488 
donkey anti-rat IgG 
(H+L) 
Dilution of the 
secondary antibody 
1:500 (2% blocking 
serum in PBS) 
1:500 (2% blocking 
serum in PBS) 
Staining time and 
temperature for 
secondary antibody 
1 hr room temperature 1 hr room temperature 
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During the optimization experiments, I tested simultaneous and sequential 
methods for staining CD4 and FOXP3, and found significantly better results 
when using sequential method as follows: 
• First blocking step: incubation with 10% normal donkey serum for 1 
hour at room temperature 
• Incubation with the CD4 antibody diluted in 2% blocking serum in PBS 
(Phosphate buffered saline) in a humidified chamber for overnight at 4ºC  
• Wash in PBS with Tween (0.05%) four times for 5 minutes each 
• Incubation with the AF555 antibody for 1 hour at room temperature in 
moist chamber in dark 
• Subsequently all staining steps were carried out in the dark. 
• Wash in PBS with Tween (0.05%) four times for 5 minutes each 
• Second blocking step: incubation with 10% normal donkey serum for 1 
hour at room temperature 
• Decant the blocking serum and incubation with the FOXP3 antibody 
diluted in 2% blocking serum in PBS for overnight at 4ºC 
• Wash in PBS with Tween (0.05%) four times for 5 minutes each 
• Incubation with the AF488 antibody for 1 hour at room temperature in 
moist chamber in dark 
• Wash in PBS with Tween (0.05%) four times for 5 minutes each 
2.11.5 Autofluorescence 
During optimization experiments, I encountered significant 
autofluorescence in the endomyocardial biopsy samples. This natural 
fluorescence is due to substances like lipofuscin that persists in paraffin sections. 
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Lipofuscin is composed of cytoplasmic yellow brown pigment granules, the 
breakdown products of unsaturated fatty acids. Apart from lipids, they also 
contain various metals including iron, copper and zinc (181). Because of their 
broad excitation and emission spectra, lipofuscin-like autofluorescence causes 
significant problems during immunofluorescence methods (182).  Hence I tried 
different quenching methods, including UV light and Sudan black at various 
concentrations as previously described (183). I found that 10 minutes incubation 
in 0.5% Sudan black in 70% alcohol reduced the autofluorescence significantly 
while slightly dampening the intensity of the immunostaining.  
Following incubation with 0.5% Sudan Black, the slides were thoroughly 
washed with PBS before nuclear counterstaining with DAPI (4', 6-diamidino-2-
phenylindole, dilactate; 1:10,000 for 2 minutes, Biotium, CA).  
The sections were again washed four times in PBS for 5 minutes each, before 
drying at room temperature. The sections were then mounted with Prolong 
Gold® anti-fade reagent (Molecular Probes®, OR). 
The entire sections were evaluated using epifluorescent microscope 
(Olympus® BX51, Japan) and images acquired using CoolSNAPHQ 
Monochrome camera (Roper Scientific®, AZ) with MetaVue™ Imaging System 
(Molecular Devices®, PA). CD4+FOXP3- and CD4+FOXP3+ cells (Tregs) were 
counted in 5-10 non-overlapping high power fields (x60). 
2.12 Immunofluorescence staining for CCL17, CCR4 and CCR8 
I attempted to co-localize Tregs with CCL17, CCR4, and CCR8 using 
immunofluorescence methods. Despite trying various methods for antigen 
retrieval and staining protocols as highlighted earlier, I could not obtain 
optimum staining for either antibody. Hence, I opted to use 
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immunohistochemistry to stain sequential cuts of the endomyocardial biopsies 
for CCL17 only. 
2.13. Immunohistochemistry 
Rabbit Polyclonal anti-human CCL17 antibody was purchased from 
AbD Serotec® (Oxford, UK). I used ImmPRESS™ peroxidase detection system 
(Vector® labs, CA) to detect CCL17 staining according to the manufacturer’s 
guidelines. The ImPRESS system is based on attaching polymerized enzymes to 
the antibodies and provides a high sensitivity with low background staining.  
The following protocol was used: 
• Dewax in xylene three times for 10 minutes each 
• Graded alcohol rehydration with 100% alcohol (twice, three minutes 
each), followed by 3 minutes each in 95% and 75% alcohol 
• Endogenous peroxidase activity was blocked by placing slides in 3% 
solution of freshly made hydrogen peroxide in 70% alcohol for 10 
minutes 
• Wash in water for 5 minutes 
• Antigen retrieval was performed using Citrate Buffer (pH 6.0) in 
microwave (high power) for 30 minutes. 
• Wash in running water for 5 minutes 
• The slides were removed from water, gently wiped around the section 
and then 200µl TBST (Tris Buffered Saline with Tween) was carefully 
added to prevent the section from drying out. Dako pen (Dako®, DK) 
was used to ring the island 
• Incubation with 2.5% normal horse serum for 30 minutes in a moist 
chamber at room temperature (blocking step) 
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• Incubation with the primary antibody (anti-CCL17 antibody) for 30 
minutes in a moist chamber at room temperature 
• Wash with TBST 
• Incubation with ImmPRESS™ peroxidase detection system (Vector® 
labs, CA) 
• Wash twice with TBST 
• ImmPACT™ Dab (diaminobenzidine) chromogen (Vector® labs, CA) 
was freshly prepared by adding 1 drop of the chromogen to 1 ml of the 
diluent.  
• Incubation with ImmPACT™ Dab for 5 minutes at room temperature 
• Wash with water for 5 minutes 
• Nuclear counter stain with Haematoxylin 
• Dehydration by placing the slides in 95% and then 100% alcohol for 2 
minutes each 
• Placing slides in Xylene for 2 minutes  
• mount using DPX resin 
• Once again, tonsil tissue was used as the positive control. The primary 
antibody was excluded for the negative control. 
With this method I obtained satisfactory staining for CCL17. The degree of 
staining was assessed and quantified on a scale of 0-3 by an expert 
histopathologist at our Pathology department. 
2.14 Statistical analysis 
All the data was analyzed using SPSS v 15. Quantitative data with 
normal distribution was described in mean and standard deviation, while non-
normal data was described with median and inter-quartile range. Similarly, 
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continuous variables from two unpaired groups with normal distribution were 
compared using T-test, otherwise Mann-Whitney U test was used. In paired 
groups, paired t-test or Wilcoxon test was utilized depending on the distribution 
of the data. One-way ANOVA was used to compare 3 or more unmatched 
groups with normal distribution, while Kruksal-Wallis test was used if the data 
from these groups was non-parametric. Chi-square test was used to compare 
categorical data.  
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Chapter 3 Th1 Chemokines are up-regulated in acute rejection 
following heart transplantation  
Abstract 
Background 
Chemokines are the mediators of immune cell trafficking, and play an 
important role in defining the alloresponse following solid organ transplantation. 
Evidence suggests that acute rejection leads to enhanced expression of certain 
chemokines in the allograft. However, there is paucity of data to show the 
effects of acute rejection on the peripheral blood chemokine levels.  
Methods 
This study analyzed the peripheral blood concentration of Th1 and Th2 
chemokines including CCL2, CCL3, CCL4, CCL5, CXCL9, CXCL10, and 
CCL11 in 50 adult heart transplant recipients at the time of routine surveillance 
endomyocardial biopsies. The peripheral blood samples were taken during the 
biopsy procedure and plasma was stored before batch analysis using bead-based 
Luminex® technology (Invitrogen®, MA). The biopsy samples were analyzed by 
experienced histopathologists at UHSM and graded between 0-4 according to 
the International Society of Heart and Lung Transplantation (ISHLT) grading 
system (180). The chemokine levels were correlated with acute rejection 
episodes using SPSS v15.  
Results 
Out of a total of 50 patients, 18 had histological evidence of acute 
cellular rejection, while the rest showed no rejection. There was no difference 
between the two groups in terms of demographics, immunosuppression and 
CMV serostatus. I found significantly higher levels of CCL2 and CCL5 (Th1 
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chemokines) in the blood samples from patients with acute cellular rejection 
compared to those with no rejection. There was no difference between the two 
groups in the levels of CXCL10, CXCL9, CCL3, CCL4 and CCL11. 
Conclusion 
In this study, I demonstrate for the first time a significant rise in the 
peripheral blood levels of specific Th1 chemokines during acute rejection in 
human heart transplant recipients. These findings further highlight the 
importance of Th1 chemokines in the alloresponse in humans and may lead to 
novel pathways for prevention and treatment of acute rejection. 
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Background 
Despite recent advances in immunosuppressive strategies and 
improvement in survival, acute rejection remains a significant cause of 
morbidity and mortality following heart transplantation (184). In addition, acute 
rejection imposes a direct and cumulative effect on the development of chronic 
rejection, also known as cardiac allograft vasculopathy, hence affecting the long 
term survival (185). Acute cellular rejection involves infiltration of mononuclear 
cells into the interstitium including T lymphocytes, monocytes and macrophages 
(186). Recent advances in the understanding of the molecular mechanisms 
governing this cellular infiltration suggest an involvement of both Th1 or Th2 
cytokines, including Interferon-gamma (IFN γ), Tumour necrosis factor-alpha 
(TNF α), or Interleukin 4 (IL4) (187-189).    
Chemokines are small chemotactic proteins responsible for directing 
various immune cells to the target environment. With over 50 chemokines and 
more than 20 corresponding receptors, the system is immensely complex yet 
highly organized. Some of the chemokines are particularly inclined to recruit 
Th1 effector cells, while others mediate Th2 inflammatory responses (190). An 
association between intragraft chemokine proteins or gene expression and acute 
allograft rejection has been documented in several models of renal, skin and 
other solid organ transplants, including the heart (186, 191-193). Further studies 
have dissected out associations between expression of Th1 chemokines such as 
CCL2, CCL3, CCL4, CCL5, CXCL9, and CXCL10, with the cellular infiltrate 
during acute rejection episodes following heart transplantation (91, 93, 94). On 
the other hand, links between Th2 chemokines and acute rejection have been 
less well defined. One study mentioned that peripheral blood levels of a Th2 
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chemokine CCL11 is associated with eosinophilia prior to acute rejection in 
human heart transplant recipients (194). Another recent study using rat model of 
acute cardiac allograft rejection showed significant increase in the intragraft 
CCL11 expression during rejection (195). 
Most of the aforementioned studies have looked at the chemokine 
proteins or gene expression within the allograft; however, there is very little 
information on the relevance of peripheral blood levels of such chemokines 
during acute rejection. Hence I prospectively investigated an association 
between the peripheral blood levels of Th1 and Th2 chemokines and moderate 
to severe acute cellular rejection in adult heart transplant recipients. 
Methods 
Patient demographics and sample collection 
50 adult heart transplant recipients undergoing routine surveillance 
endomyocardial biopsies were recruited. The exclusion criteria included patients 
with acute infections, severe hepatic dysfunction, and failure to obtain an 
informed consent. The timing of the biopsy was determined according to the 
clinical need, and it was performed via right internal jugular route under 
fluoroscopy guidance. Just prior to the biopsy a sample of the peripheral blood 
was obtained in an EDTA (ethylene diamine tetra-acetic acid) vacutainer. 
Plasma was separated from the blood by centrifuge at 1500 RPM (rev per 
minute) for 10 minutes. Approximately 500 microliters aliquot of the separated 
plasma was immediately stored in polypropylene tube at -80º Celsius for batch 
analysis. The biopsy samples were fixed in 4% formalin and transferred to the 
pathology department for routine histological grading according to the ISHLT 
grading system (180). The patients were thus divided into two groups: Group 1 
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(with acute rejection) and Group 2 (showing no rejection). Clinical data was 
collected from patient notes for risk stratification. The use of 
immunosuppressive agents (Prednisolone, Cyclosporine, Tacrolimus, 
Mycophenolate Mofetil and Azathioprine), and haematological white blood cell 
counts (neutrophils, lymphocytes, monocytes, eosinophils, basophils and 
platelets) were also collected. 
The study was designed to investigate the differences in the peripheral 
blood chemokine levels between stable, non-rejecting patients and those with at 
least grade 2R (moderate rejection). Due to the very limited number of patients 
with this degree of rejection, it was not possible to obtain sufficient number of 
consecutive samples during the limited time of the study. Hence, patient’s 
consent was obtained for using some plasma aliquots stored over a period of 
nearly 3 years (between 2005 and 2007) for the purpose of the immunological 
marker study in the Transplant department at my hospital. With this method, I 
could obtain a group of 18 heart transplant recipients with grade 2R rejection, to 
compare against a randomly selected group of 32 heart transplant recipients with 
no rejection. Hence, the study was part prospective, part retrospective, 
observational study. Due to the same reason of limited number of samples with 
grade 2R rejection, it was not possible to sufficiently power the study for 
observing minor effect size for the individual chemokines. The study was 
approved by the local regional ethics committee and performed according to the 
declaration of Helsinki. All participants provided written informed consent. All 
tissue samples were stored according to the Human Tissue act.  
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Luminex Immunoassay 
I used Luminex® (Invitrogen®, MA) to measure the levels of Th1 and 
Th2 chemokines including CCL2, CCL3, CCL4, CCL5, CXCL9, CXCL10, and 
CCL11 in the plasma separated form the peripheral blood samples. The 
Luminex® implies multiplex solid phase immunoassays using spectrally 
encoded, antibody conjugated beads (figure 2.1, chapter 2). This technology is 
capable of simultaneous measurement of several proteins in a single well and is 
now well described (196, 197). The method is capable of measuring the 
chemokine levels with a high sensitivity and low interassay variability, as 
mentioned in chapter 2.   
Statistical analysis 
All the data was analyzed using SPSS. The two groups were compared in 
terms of demographics, clinical data and serum chemokine levels. Students t test 
or Mann-Whitney U test were used for comparing the continuous data 
depending on the normality of distribution of the variables, while Chi-square test 
was used for comparing the categorical variables. A p-value of less than 0.05 
was considered statistically significant.  
Results 
Group 1 (with evidence of grade 2R rejection on the endomyocardial 
biopsy) comprised of 18 patients, while Group 2 included 32 patients with no 
evidence of rejection on the endomyocardial biopsy. Clinical and laboratory data 
was available for all the patients. I found no difference between the two groups 
in terms of the demographic data. The two groups were similar in terms of 
immunosuppression and CMV serostatus as well. Table 3.1 summarizes some of 
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the demographic variables while table 3.2 shows the peripheral blood counts for 
the two groups. 
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Table 3.1 Demographic data for rejecting versus non-rejecting patients. 
Age is described in mean (standard deviation), while the duration since 
transplant is shown in median (25th, 75th percentiles) due to non-parametric 
distribution. (CNI, Calcineurin inhibitors) 
 Group 1 (n=18) Group 2 (n=32) P value 
Age (years) 49.83 (13.35)*  50.63(13.01)* 0.55 
Duration since 
transplant (days) 
126.0 (27.5, 185.25) 174.5 (59.0, 558.0) 0.08 
Male 77.8% 75.0% Sex:  
Female 22.2% 25.0% 
0.82 
ICM 50% 53.12% 
DCM 44.4% 37.5% 
Pre-
transplant 
diagnosis Others 5.6 9.37% 
0.83 
Positive 5.5% 21.8% CMV 
serostatus Negative 94.5% 78.2% 
0.13 
Cyclo 88.8% 87.5% CNI 
FK 11.1% 12.5% 
0.87 
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Table 3.2 Comparison of the peripheral blood counts between the two 
study groups.  
* denotes data in mean (±standard deviation), § data in median (25th, 75th 
percentiles) 
 
 Group 1 (n=18) Group 2 (n=32) P value 
WBC (x109/l) 6.36 (1.84)* 7.14 (3.2)* 0.38 
Neutrophils (x109/l) 4.64 (1.59)* 5.64 (2.92)* 0.39 
Lymphocytes (x109/l) 0.74 (0.5, 0.9) § 0.62 (0.5, 0.91) 0.69§ 
Monocytes (x109/l) 0.37 (0.09)* 0.6 (0.38)* 0.14 
Eosinophils (x109/l) 0.1 (0.07, 0.1)§ 0.05 (0.02, 0.1) § 0.19 
Basophils (x109/l) 0.04 (0.03)* 0.02 (0.02)* 0.14 
Platelets (x109/l) 251.53 (94.93) 230.85 (92.62) 0.51 
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When comparing the chemokine levels between the two groups, I found that 
patients with acute rejection had significantly higher peripheral blood levels of 
CCL2 and CCL5 (Fig 3.1, 3.2). However, there was no significant difference in 
the levels of CCL3, CCL4, CXCL9, CXCL10 and CCL11 between the two 
groups.  
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Fig 3.1  Box plot showing mean concentration of CCL2 in the 
peripheral blood samples in acute (n=18) versus non-rejecting (n=32) heart 
transplant patients.  
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Fig 3.2  Box plots showing mean peripheral blood concentration of 
CCL5 in acute (n=18) versus non-rejecting (n=32) heart transplant patients. 
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Discussion 
Chemokines are important mediators of leucocyte trafficking, and 
undoubtedly play a key role in acute rejection following solid organ 
transplantation. Despite the up-regulation of various chemokines and their 
receptors in the allograft during rejection, there had yet been no evidence to 
suggest any associations with allograft rejection and the peripheral blood 
concentrations of chemokines. Herein I demonstrate for the first time an 
association between peripheral blood chemokine levels and acute cellular 
rejection following heart transplantation.  
As previous evidence suggests that acute rejection following solid organ 
transplantation may involve Th1 or Th2 response (198), I evaluated a range of 
Th1 and Th2 chemokines in the peripheral blood of rejecting and non-rejecting 
patients. Interestingly, only CCL2 and CCL5 concentrations were significantly 
elevated during the acute rejection episode, while I found no associations with 
the levels of CXCL9, CXCL10, CCL3, CCL4 and CCL11. This finding is 
interesting because previous authors have reported that intragraft expressions of 
CCL2 (a ligand for CCR2), and CCL5 (ligands for CCR1 and CCR5) have been 
associated with cellular infiltration that lead to acute rejection following heart 
transplantation (91).  
The findings of my study further complement a previous study by 
Karason et al, who found that the peripheral blood levels of CXCL9 and 
CXCL10 did not correlate with acute rejection, despite a significant up-
regulation of corresponding genes in the rejecting myocardium (98). Similar to 
Karason et al, my study did not demonstrate an association between peripheral 
blood CXCL9 and CXCL10 levels and acute rejection. 
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study was to define non-invasive biomarkers of rejection in heart transplant 
recipients, hence they selected CXC chemokines that are well described to up-
regulate during acute rejection (93, 97). However, they did not evaluate 
relationship between CCL2 and CCL5 and acute rejection. Hence, my novel 
findings may help in determining valuable non-invasive adjuncts for the 
detection of acute rejection in solid organ transplantation. 
Apart from transplantation, various studies have documented serum 
chemokine levels as indicative of a systemic response to the pathological state, 
including amyotrophic lateral sclerosis (199) rheumatoid arthritis (200) hepatic 
inflammation (201) and psoriasis (202). While none of the included patients in 
my study had significant systemic inflammation as shown by the normal 
peripheral blood white cells and neutrophil counts, one can argue that more 
stringent inclusion criteria and measuring high-sensitivity C-reactive protein 
(CRP) might have helped in excluding any confounding factors. I acknowledge 
that this remains one of the limitations of this study. 
The findings of this study may still have implications towards prevention 
of acute rejection or induction of allograft tolerance. Experimental models have 
suggested that allograft survival can be prolonged by blocking specific 
chemokine pathways. For example, Horuk et al demonstrated that treating a rat 
model of heart transplant rejection with BX471 (an orally active CCR1 
antagonist) resulted in significant prolongation of allograft survival (p=0.004), 
with further synergistic effects when used with a sub-therapeutic dose of 
cyclosporin (p=0.0009) (203). The study suggested that BX471 inhibits the 
adhesion of activated mononuclear cells to inflamed epithelium. Another study 
used TAK779 (a CCR5 and CXCR3 antagonist) on murine model of cardiac and 
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islet allograft rejection. They also found a significant dampening of the local 
immune response, reduced infiltration of CD4, CD8 and CD11c cells into the 
allograft, and significant prolongation of the allograft survival (204). Hence, 
cellular infiltration of the allograft can be altered by interfering with the 
systemic effects of CCL2 and CCL5, thus helping to prevent allograft rejection. 
One limitation of my study was the small underpowered sample size due 
the reasons explained above. In addition, I also acknowledge the fact that this 
study was conducted on plasma instead of serum samples. However, I believe 
that this small observational study still provides an important finding relevant to 
the heart transplant population.  
To conclude, I herein demonstrate that acute rejection in human heart 
transplant recipients lead to a significant rise in the peripheral blood levels of 
Th1 chemokines CCL2 and CCL5, without any significant change in the levels 
of CCL3, CCL4, CXCL9, CXCL10 and CCL11. Further studies may 
demonstrate if these findings can be used for non-invasive determination of 
acute rejection, or to prolong allograft survival via blocking specific chemokine 
pathways.  
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Chapter 4 The effects of immunomodulatory drugs on peripheral blood 
Treg levels in adult heart transplant recipients 
Abstract 
Background 
Establishing an immunologic tolerance is the holy grail of 
transplantation. The CD4+CD25brightFOXP3+ T cells (Tregs) are documented to 
play a pivotal role in the allograft tolerance. At present various 
immunosuppressive medications in different combinations are used to prevent 
rejection. These are, however, associated with debilitating side effects, including 
hypercholesterolemia. As a result, statins are frequently used following heart 
transplantation. Previous studies have shown conflicting evidences regarding the 
effects of these medications on the peripheral blood levels of Tregs. 
Methods 
90 stable adult heart transplant recipients were prospectively recruited 
for this observational study. All patients received standard immunosuppression 
according to the unit protocol, including cyclosporin or tacrolimus (CNI), 
Mycophenolic acid (MPA) or azathioprine (Aza), and Prednisolone (Pred). 
Statin use was determined according to clinical necessity and tolerability. The 
peripheral blood samples were collected in EDTA vacutainer during routine 
follow up and Tregs were phenotyped by cell surface expression of CD4 and 
CD25, and intracellular FOXP3 expression.  
Results 
Following risk stratification, I found no difference in the levels of Tregs 
between patients taking cyclosporin (n=78) or tacrolimus (n=12). Patients were 
then divided into three groups according to the use of CNI+MPA±Prednisolone 
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(Group1), CNI+Azathioprine±Prednisolone (Group 2), or CNI+Prednisolone 
(Group 3). Once again I found no difference in Treg levels or FOXP3 expression 
between the three groups. However, patients who were treated with a statin 
(n=75) had significantly reduced numbers of circulating CD4+CD25brightFOXP3+ 
Tregs compared to patients not treated with a statin (n=15, p=0.01). The 
percentage of Tregs in the T cell compartment was also significantly lower 
compared to the non statin group (p=0.02). 
Conclusion 
In this observational study, I found no effects of immunosuppressive 
medications on the numbers of circulating Tregs in patients following heart 
transplantation. However, statin use was associated with significantly reduced 
peripheral blood Treg counts. This may significantly affect recipient immune 
responses to graft tissue, as Tregs promote specific T cell unresponsiveness to 
alloantigen, via modulation of allospecific CD4 T cell responses. 
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Background 
The alloresponse following transplantation comprises an effector arm to 
reject the transplanted organ, and a regulatory arm that checks the effector 
response and induces and maintains homeostasis. The CD4+CD25brightFOXP3+ T 
cells (Tregs) are widely recognized as the most important part of the regulatory 
armamentarium, maintaining specific unresponsiveness and operational 
tolerance to donor antigen (30, 33). These cells comprise 5-10% of the 
peripheral blood CD4+ compartment in humans (35). Studies have demonstrated 
that the peripheral blood counts of Tregs increase following solid organ 
transplantation, and that these levels vary according to the state of 
immunological stability (205).  
Another factor that may have an effect on Tregs is the use of various 
non-specific immunosuppressive agents such as Cyclosporin, Tacrolimus, 
Mycophenolic acid derivatives, Azathioprine and Prednisolone, which are still 
widely used to prevent or treat rejection (206). Cyclosporin and Tacrolimus 
(together labelled as Calcineurin inhibitors or CNI) bind to the intracellular 
immunophilins (calcineurin), blocking the T cell receptor (TCR)-dependent 
activation of the calcineurin, thus inhibiting nuclear translocation of the Nuclear 
factor of activated T cells (NF-AT) and suppressing T cell activation and 
cytokine gene transcription, including Interleukin 2 (IL2) (207).  Mycophenolic 
acid (MPA) pro-drugs include Mycophenolate mofetil (MMF or CellCept®) and 
Myfortic®, the slow release preparation. MPA are powerful inhibitors of Inosine 
Monophosphate Dehydrogenase (IMDH), a rate-limiting enzyme in de-novo 
synthesis of guanosine nucleotides, particularly in the activated T and B cells 
(208, 209). Azathioprine acts as a non-specific anti-proliferative drug by the 
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formation of intracellular thiopurine ribonucleotides (210). There is conflicting 
evidence in the literature regarding the effects of immunosuppression on Tregs.  
Some studies suggest a negative effect of these immunosuppressive agents, 
particularly the CNI on the Treg population (211). However, in-homogeneity to 
define Tregs phenotype leads to considerable confusion and further studies are 
required.  
Hyperlipidaemia is another significant problem in the post heart 
transplant population and occurs for several reasons which include inappropriate 
diet, reduced physical activity and adverse effects of immunosuppressive 
therapy, especially from Cyclosporine and steroids (212). Hyperlipidaemia has 
also been associated with early onset vasculopathy and rejection (213).   
As a result, between 60 to 80 percent of cardiac transplant recipients 
receive cholesterol lowering agents (214). The most frequently used agents are 
inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, 
commonly referred to as statins. In addition to lipid lowering effects, statins 
have been reported to modulate immune cells which are directly involved in 
graft rejection, such as macrophages, T cells, and natural killer (NK) cells (215). 
However, the effects of statins on Tregs are yet to be determined.  
On these grounds I prospectively explored the effects of routine 
immunosuppression and statin administration on the numbers of peripheral 
blood Tregs following heart transplantation.  
Methods 
90 stable adult heart transplant recipients were prospectively recruited 
into this observational, non-randomized study. The exclusion criteria included 
acute rejection, acute infections, severe hepatic dysfunction, and failure to give 
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informed consent. All patients received standard immunosuppression according 
to our unit protocol comprising cyclsopsorin or tacrolimus, MPA or Aza, and 
Prednisolone. Treatment and the doses of statins were determined by clinical 
necessity as governed by the medical team. Clinical data was collected from the 
patient notes. Demographic data (age, gender, time post transplantation, pre 
transplant diagnosis) were collected for risk stratification. The use of 
immunosuppressive agents and haematological white blood cell counts 
(neutrophils, lymphocytes, monocytes, eosinophils, basophils and platelets) were 
collected.  
Flow Cytometry 
Sample Collection: Whole blood was collected into EDTA vacutainers (BD) via 
venepuncture from patients attending for the routine follow up. 
Sample Preparation: Peripheral blood mononuclear cells (PBMC) were isolated 
from whole blood sample by density gradient centrifugation method using 
Ficoll-Paque as previously described (173). 100µl of PBMC were stained with 
anti-human CD4 phycoerythrin-Cy5 (PE-Cy5) and anti CD25 phycoerythrin-
Cy7 (PE-Cy7) for 30 minutes in the dark (to avoid denaturing by ultra violet 
light). Staining with fluorescein isothiocyanate (FITC)-conjugated anti-human 
FOXP3 (e-Bioscience, UK) was performed with the fixation and 
permeabilization solutions according to the manufacturer’s guidelines. The 
combinations of mouse IgG1 PE-Cy5, PE-Cy7, and FITC were used as isotype 
controls. Flow cytometric analysis was performed using a BD™ LSR II flow 
cytometer with linear forward scatter (FSc), linear side scatter (SSc), and log 
fluorescence 1 (FL1), 2 (FL2) and 3 (FL3) detection. A standard FS/SS 
lymphocyte gating strategy was used (fig 2.5), along with software generated 
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bright and dim gating strategy. Data was collected for either a maximum of 300 
seconds or ten thousand events for all antibody combinations.  
Laboratory Data Analysis: Additional gating strategies (including CD25 bright 
subsets (fig 2.6-2.10) and data analysis were performed using BD FACSDiva™ 
software EXPO32 ADC Analysis software (Beckman Coulter). Tregs were 
grouped as CD4+CD25brightFOXP3+. Fluorescence values from total number of 
cells were calculated into Microsoft Excel. Treg counts and FOXP3 mean 
expression levels were compared to the various demographic data and 
immunosuppressive data at the time of sampling. 
Results 
The cohort included 73 males (81.1%) and 17 females (18.9%), at a mean age of 
52.8 (± 13.7) years, and mean duration 8.7 (± 6.0) years following 
transplantation. There were no correlations of age and duration since transplant 
with the counts of CD4+ cells, Tregs, or CD4+CD25- effector cells, or the Treg 
FOXp3 expression. The cell counts or the FOXP3 expression were also not 
correlated with any of the demographic variables or the immunosuppressive 
medications (tables 4.1-4.6) 
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Table 4.1 The peripheral blood CD4+, CD4+CD25-, Treg, and FOXP3 
expression according to the sex (n=90) (* denotes data in mean ± standard 
deviation, rest of the data is expressed in median (25th, 75th percentile) due to 
non-parametric distribution). 
 
 
Cell types Male 
(81.1%) 
Female 
(18.9%) 
P value 
CD4+ 1128.49 (809.69)* 1549.35 
(1223.31)* 
0.24 
Tregs 3.0 (1.0, 14.0) 7.0 (2.5, 23.0) 0.15 
Tregs %  
of CD4+CD25bright 
17.61 (15.55)* 18.39 (13.69)* 0.85 
Tregs % of CD4 0.6 (0.1, 1.35) 0.6 (0.35, 1.6) 0.45 
Treg FOXp3 
expression 
1494.0 (1252.5, 
1919.5) 
1326 (1081.0, 
1757.0) 
0.15 
CD4+CD25- 661 (315.5, 980.0) 960 (293.5, 
1503.0) 
0.28 
CD4+CD25- % of 
CD4 
61.44 (18.8)* 60.53 (15.53)* 0.85 
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Table 4.2 The peripheral blood CD4+, CD4+CD25-, Treg, and FOXP3 
expression according to the presence or absence of Diabetes (n=90) (* 
denotes data in mean ± standard deviation, rest of the data is expressed in 
median (25th, 75th percentile). 
 
Cell types Diabetes (15.6 %) No diabetes (84.4%) P value 
CD4+ 1468.35 (1169.9)* 1160.02 (853.8)* 0.24 
Tregs 5.5 (2.0, 15.75) 3 (1.0, 16.5) 0.27 
Tregs %  
of CD4+CD25bright 
17.62 (13.3)* 17.79 (15.55)* 0.96 
Tregs % of CD4 0.6 (0.35, 1.85) 0.5 (0.1, 1.37) 0.38 
Treg FOXp3 
expression 
1423.5 (1194.0, 
1672.7) 
1487.5 (1214.0, 
1923.0) 
0.35 
CD4+CD25- 818.5 (302.25, 
1018.25) 
678 (317.0, 1122.0) 0.81 
CD4+CD25- % of 
CD4 
57.65 (16.66)* 61.93 (18.44)* 0.42 
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Table 4.3 The peripheral blood CD4+, CD4+CD25-, Treg, and FOXP3 
expression according to the presence or absence of hypertension (n=90) (* 
denotes data expressed in mean ± standard deviation, rest of the data is 
expressed in median (25th, 75th percentile). 
 
Cell types Hypertension 
(87.8%) 
No hypertension 
(12.2%) 
P value 
CD4+ 1092 (483.0, 
1641.0) 
1297 (644, 2188) 0.33 
Tregs 3.0 (1.0, 12.0) 18.0 (5.0, 22.0 ) 0.054 
Tregs %  
of CD4+CD25bright 
17.68 (15.34)* 18.32 (14.37)* 0.89 
Tregs % of CD4 0.5 (0.1, 1.3) 0.8 (0.6, 2.1) 0.15 
Treg FOXp3 
expression 
1479.0 (1212.0, 
1923.0) 
1448.0 (1109.5, 
1672.5) 
0.35 
CD4+CD25- 686.0 (311.0, 
1022.0) 
680.0 (320.0, 
1475.0) 
0.64 
CD4+CD25- % of CD4 62.08 (18.49)* 55.4 (14.94)* 0.25 
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Table 4.4 The peripheral blood CD4+, CD4+CD25-, Treg, and FOXP3 
expression according to renal impairment (estimated GFR greater or less than 
60) (n=90) (* denotes data expressed in mean ± standard deviation, rest of the 
data is expressed in median (25th, 75th percentile). 
 
Cell types eGFR <60 
(83.3%) 
eGFR>60 
(16.7%) 
P value 
CD4+ 1248.78 (924.86)* 1004.0 (825.63)* 0.34 
Tregs 3.0 (1.0, 17.0) 4.0 (2.0, 12.0) 0.97 
Tregs %  
of CD4+CD25bright 
16.99 (14.66)* 21.51 (17.36)* 0.29 
Tregs % of CD4 0.89 (1.07)* 0.96 (0.80)* 0.81 
Treg FOXp3 
expression 
1460.0 (1189.7, 
1762.7) 
1811.5 (1379.5, 
2120.0) 
0.06 
CD4+CD25- 680.0 (320.0, 1050.0) 861.0 (56.0, 
1212.0) 
0.74 
CD4+CD25- % of 
CD4 
60.69 (18.22)* 64.16 (18.15)* 0.50 
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Table 4.5 The peripheral blood CD4+, CD4+CD25-, Treg, and FOXP3 
expression according to the Pre-transplant diagnosis (n=90) (* denotes data 
expressed in mean ± standard deviation, rest of the data is expressed in median 
(25th, 75th percentile). 
 
Cell type DCM 
(n=49) 
ICM 
(n=33) 
VHD 
(n=3) 
Others 
(n=5) 
p 
value 
CD4+ 1018 (497, 
1662) 
1148 (559, 
1680) 
1109 (23, 
1567) 
1627 (494, 
2534) 
0.83 
Tregs 4 (1, 21) 3 (1, 8.5) 2 (0, 24) 20 (3, 26) 0.26 
Tregs %  
of 
CD4+CD25bright 
16.7 (5.9, 
30.5) 
12.5 (2.5, 
27.3) 
7.1 (0, 
7.4) 
20 (2.7, 
28.8) 
0.27 
Tregs % of CD4 0.6 (0.1, 
1.7) 
0.4 (0.1, 
1.1) 
0.2 (0, 
1.5) 
1.4 (0.4, 
1.8) 
0.16 
Treg FOXp3  
expression 
1475 
(1263.5, 
1773) 
1464 (118, 
2063) 
3157 
(1801, 
4514) 
1448 
(1119, 
3188) 
0.38 
CD4+CD25- 661 (298, 
1033.5) 
771 (311, 
1132) 
519 (1, 
780) 
676 (260, 
1371.5) 
0.75 
CD4+CD25- %  
of CD4 
62.1 (50.3, 
74.6) 
69.5 (56.5, 
73.8) 
33.1 (4.3, 
70.3) 
45.1 (33.7, 
64.1) 
0.08 
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Table 4.6 The peripheral blood CD4+, CD4+CD25-, Treg, and FOXP3 
expression according to the type of CNI (n=90) (* denotes data expressed in 
mean ± standard deviation, rest of the data is expressed in median (25th, 75th 
percentile) due to non-parametric distribution). 
 
Cell type Cyclosporin 
(n=78) 
Tacrolimus 
(n=12) 
p 
value 
CD4+ 1127 (528, 1676) 959.5 (629.7, 1651.7) 0.84 
Tregs 4 (1, 15) 3 (1, 22) 0.84 
Tregs %  
of CD4+CD25bright 
17.5 (15.4)* 19 (13.6)* 0.76 
Tregs % of CD4 0.5 (0.1, 1.3) 0.9 (0.2, 1.7) 0.37 
Treg FOXp3  
expression 
1464 (1216, 1886.5) 1632 (106, 1923) 0.93 
CD4+CD25- 683 (302, 1062) 636 (364, 1149) 0.96 
CD4+CD25- %  
of CD4 
60.7 (19.0)* 64.9 (10.7)* 0.45 
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Patients were further divided into three groups according to the 
immunosuppressive regimen: CNI+MPA±Prednisolone (Group1, n=55), 
CNI+Azathioprine±Prednisolone (Group 2, n=15), or CNI+Prednisolone (Group 
3, n=20). Following risk stratification, the three groups showed no difference in 
terms of CD4, Treg or CD4+CD25- effector cell counts, or Treg FOXP3 
expression (table 4.7).  
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Table 4.7 Distribution of the peripheral blood CD4+, CD4+CD25-, Treg, 
and FOXP3 expression according to the immunosuppression protocol: 
Group 1= CNI+MPA±Pred, Group 2 = CNI+Aza±Pred, Group 3 = 
CNI+Pred. (* denotes data in mean ± standard deviation, rest of the data is 
expressed in median (25th, 75th percentile).  
 
Cell type Group 1 
(n=55) 
Group 2 
(n=15) 
Group 3 
(n=20) 
p value 
CD4+ 971 (555, 
1609) 
1297 (1018, 
1849) 
954 (271, 
1706)) 
0.27 
Tregs 4 (2, 15) 6 (2, 24) 3 (0.2, 16) 0.70 
Tregs %  
of 
CD4+CD25bright 
16.6 (15.1)* 19.3 (14.3)* 19.8 (16.3)* 0.66 
Tregs % of CD4 0.9 (1.1)* 0.9 (0.8)* 0.8 (0.8)* 0.91 
Treg FOXp3  
expression 
1510 (1195.2, 
1838.7) 
1414 (1205, 
1989.5) 
1464 (1287, 
1923) 
0.96 
CD4+CD25- 655 (311, 
943) 
906 (549, 
1323) 
1650 (148.5, 
1213.5) 
0.20 
CD4+CD25- %  
of CD4 
60.5 (15.9)* 66.6 (18.1)* 59.1 (23.5)* 0.43 
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The effects of statins on Tregs 
As a sub-group analysis, I compared the patients taking statins (ST, n=75) 
versus patients not on statins (NOST, n=15). The patients in ST group had been 
on statins for more than 6 weeks prior to inclusion in the study. NOST patients 
had never been treated with any cholesterol lowering agents. Clinical and 
laboratory data was available for all study participants. There were no 
differences in clinical or demographic characteristics between the two treatment 
groups as shown in table 4.8. Both groups were at a similar time post 
transplantation (ST group were a mean of 3049 ± 2139 days since 
transplantation and NOST patients were a mean of 3994.3 ± 2490.4 days since 
transplantation (p=0.1). In terms of the types of statins, 57.3% of ST patients 
were taking Pravastatin, 26.7% were taking Atorvastatin, 10.7% were on 
Simvastatin, and the rest on Fluvastatin or Rosuvastatin. All patients received 
prednisolone (pred), ranging from 5 to 15 mg per day, with no difference in pred 
dose between the 2 study groups (6.5 mg/ day vs. 6.0 mg/day for ST and NOST 
respectively p=0.6). When comparing treatment with routine 
immunosuppressive agents, 85.3% (ST) vs. 93.3% (NOST) patients received 
Cyclosporine (CsA), and 14.7% (ST) vs. 6.7% (NOST) received Tacrolimus 
(Tac). When comparing secondary immunosuppressive agents, I found that 16% 
(ST) vs. 20% (NOST) patients received Azathioprine (Aza), and 62.7% (ST) vs. 
53.3% (NOST) received Mycophenolate Mofetil (MMF). However, there were 
no differences between CsA/Tac administration and numbers of CD4+ 
(p=0.845), CD4+25bright (p=0.840), Treg (p=0.844), Treg mean FOXP3 
expression (0.935), Treg percentage of CD4 (p=0.378) or CD4+CD25- (p=0.96) 
lymphocytes, or MMF/Aza administration and numbers of CD4+ (p=0.124), 
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CD4+25bright (p=0.875), Treg (p=0.499), Treg mean FOXP3 expression (0.833), 
Treg percentage of CD4 (p=0.954) or CD4+CD25- (p=0.068) lymphocytes.  
When comparing T cell phenotypes between ST and NOST, I found that the 
patients in NOST group had significantly higher numbers of circulating Tregs 
compared to ST patients (Fig 4.1). Interestingly, the number of circulating CD4+ 
cells (even CD4+CD25bright) without FOXP3 did not differ between the two 
groups. I also looked at the relative proportion of Tregs (Tregs as the percentage 
of CD4+CD25bright cells) between ST and NOST, and again found a significantly 
lower proportion of Tregs in the ST group (p=0.047) (Fig 4.2) 
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Table 4.8 Demographics according to the use of Statins 
(* denotes data in mean (standard deviation), eGFR = estimated glomerular 
filtration rate)  
 
  Statin group (n=75) No statin group 
(n=15) 
P 
value 
Age (years) 53.2 (13.8)* 51.1 (13.6)* 0.58 
Male 81.3% 80.0% 0.68 
Pre-Transplant 
diagnosis 
DCM (52.0%) ICM 
(38.7%), Others 
(9.3%) 
DCM (66.7%) ICM 
(26.7%), Others 
(6.7%) 
0.46 
Duration since 
Transplant (days) 
3049 (2139.7)* 3994.3 (2490.4)* 0.14 
Hypertension 86.7% 93.3% 0.68 
Diabetes Mellitus 17.3% 6.7% 0.45 
eGFR 45.3 (17.7)* 43.4 (19.2)* 0.71 
Serum 
Cholesterol 
5.0 (0.9) * 5.2 (1.3) * 0.70 
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Table 4.9 Immunosuppressive medications in patients with and without 
statins. (* denotes data in mean ± standard deviation, § shows data in median 
(25th, 75th percentile) due to non-parametric distribution).   
 
  Statin group 
(n=75) 
No statin group 
(n=15) 
P value 
Cyclosporin (as % of 
CNI) 
85.3% 93.3% 0.68 
Mycophenolic acid 62.7% 53.3% 0.79 
Azathioprine 16% 20% 0.7 
Cyclosporin level 81 (53, 114)§ 101 (60, 149) § 0.28 
Prednisolone dose 
(mg) 
6.5 (4.4)* 5.9 (5.2) * 0.68 
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Table 4.10 Peripheral blood counts in patients with and without statins. 
All data is expressed in mean (standard deviation).  
 
  Statin group 
(n=75) 
No statin group 
(n=15) 
P 
value 
WBC (x109/l) 7.19 (2.05) 6.62 (2.78) 0.37 
Neutrophil (x109/l) 5.15 (2.02) 4.43 (2.68) 0.28 
Lymphocytes (x109/l) 1.26 (0.67) 1.33 (0.52) 0.74 
Monocytes (x109/l) 0.65 (0.19) 0.69 (0.25) 0.80 
Eosinophils (x109/l) 0.1 (0.09) 0.13 (0.08) 0.54 
Basophils (x109/l) 0.02 (0.01) 0.02 (0.01) 0.92 
Platelets (x109/l) 242.96 (57.8) 238.29 (102.9) 0.48 
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Fig 4.1  Box plot comparing peripheral blood Treg counts in patients 
with or without statins.  
Group 0 denotes patients not on statins (n=15), while the group 1 denotes 
patients on statins (n=75).    
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Fig 4.2  Box plot showing peripheral blood Tregs as percentage of the 
CD4+CD25bright lymphocytes in patients with or without statins.  
Group 0 denotes patients not on statins (n=15), while the group 1 denotes 
patients on statins (n=75).    
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Discussion 
This is the first study in the literature describing an immunomodulatory 
effect of statins on Tregs following heart transplantation. In terms of 
immunosuppressive strategies, my results are consistent with the previously 
published work in lung transplant cohort, showing no association between the 
individual or combinations of immunosuppressive medications with the 
peripheral blood Tregs (205). I also demonstrate a lack of association between 
immunosuppression and FOXP3 expression in Tregs, which is considered as the 
marker of immunoregulatory potential.  
The implications of my results to the solid organ transplant recipient are 
widespread. Tregs have been reported to induce and maintain immunologic 
tolerance to alloantigen. (6). Tregs also disrupt the allospecific T cells that play a 
pivotal role in the cellular responses leading to graft rejection. This occurs via 
the deletion of clonally expanded allospecific T cells, or the induction of 
ignorance and/or anergy (7). The removal of Tregs in murine models results in 
the activation of self reactive T cells causing autoimmune diseases such as 
gastritis with pernicious anaemia, Hashimotos thyroiditis, insulin dependent 
diabetes mellitus, systemic lupus erythematosis and rheumatoid arthritis (22). 
It has been extensively documented that IL2 confers optimal suppressive 
function to the Tregs, partly via intracellular kinase dependent pathways (216). 
Hence non-specific suppression of IL2 through CNI is expected to render 
diminished induction and function of Tregs, alongside inhibition of the effector 
T cell population. Indeed, Baan et al showed that CNI inhibit in-vitro induction 
of FOXP3 in a mixed lymphocyte reaction (211). Subsequent in-vivo studies 
showed the inhibitory effects of cyclosporin administration on peripheral blood 
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Treg population in a transplant cohort (217, 218). However, the effects of 
tacrolimus on Tregs are still controversial. One study looking at 
ischemia/reperfusion (I/R) model showed that the treatment with tacrolimus 
prevented I/R injury along with an augmentation of the Treg population (219).  
A somewhat similar observation was made by another study where in-vitro 
proliferation of CD4+ cells was observed. Tacrolimus inhibited TCR-stimulated 
cell division in the conventional CD4+ cells, but Tregs showed enhanced cell 
division in the presence of Tacrolimus (220). Since all the patients in my study 
were taking CNI as primary immunosuppression, I could not elicit a difference 
with non-CNI group. However, I found no difference in Treg counts or FOXP3 
expression in patients taking CsA or Tacrolimus.  
Corticosteroids (CS) (such as Prednisolone, methyl Prednisolone) have 
long been used in transplant patients due to potent immunosuppressive and anti-
inflammatory properties. CS exert their immunosuppressive effects via several 
direct and indirect pathways, leading to the modulation of adhesion molecules, 
suppression of cytokine synthesis, and T cell activation (221). There is evidence 
to suggest that part of the CS mechanism of action may involve an augmentation 
of the Treg population. This was shown in a study where administration of CS to 
asthmatic patients resulted in a significant increase in the expression of FOXP3 
mRNA (222). In another study using  murine model of autoimmune 
encephalomyelitis, short term treatment with Dexamethasone and IL2 
significantly enhanced the proportion of Tregs in peripheral lymphoid tissue and 
prevented the disease (223). However, there is a paucity of data to suggest CS 
effects on Treg in human transplant patients. In the present study, I did not find 
any correlations of Tregs with the Prednisolone dose. However, the study was 
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not sufficiently powered to measure the effect, and further studies with larger 
population are required.  
In order to optimise immunosuppression and reduce the side effects, use 
of multi-drug immunosuppressive regimen targeting different pathways is a 
common strategy following clinical transplantation. The MPA compounds 
(MMF® or Myfortic®) target de novo synthesis of guanosine nucleotides by 
inhibiting IMDH (209). Since the lymphocytes are more dependent on this 
pathway than other cells such as neutrophils, the cytostatic effects are more 
specifically pronounced in lymphocytes, particularly the activated lymphocytes. 
In addition, MPA drugs induce apoptosis of activated lymphocytes, suppress the 
expression of certain adhesion molecules and prevent tissue damage by 
production of NO (208).  Hence, MPA drugs have largely replaced Azathioprine 
that induces non-specific DNA and nucleotide synthesis resulting in significant 
side effects (224). In addition, the use of MPA has now been acknowledged as a 
CNI-sparing strategy with potentially less side effects, as shown in a recent large 
randomized control trial (225). Taking it further, there is evidence to suggest 
that MPA drugs may actually be helpful in promoting Treg population compared 
to CNI-based regimen. This was shown by Demirkiran et al in their study on 
liver transplant recipients, where conversion from CNI to MMF resulted in an 
enrichment of the peripheral blood Tregs (226). However, my present work did 
not show any correlations between either the use or the dose of MPA and the 
peripheral blood counts of Tregs. One possible reason may be the effect of the 
concomitant CNI drugs. Also, the Demirkiran study was conducted in liver 
transplant patients with possible cohort differences compared to my study. In 
this context, I want to emphasize that small sample size was one of the main 
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limitations of my study. Hence it could not be statistically powered to detect an 
absolute difference between the Treg counts for each combination of 
immunosuppressive medications. 
An interesting finding in my study was the effect of statins on Treg 
population. In a non-transplant setting, statins have largely been used as the 
cholesterol lowering agents with an ability to halt the progression or even induce 
regression of atherosclerotic plaques (227-229). The mechanism of 
atherosclerotic regression is considered to occur via the reduction of low density 
lipoprotein levels (LDL-C) and the increase of high density lipoproteins (HDL-
C) (230). However, separate from a lipid altering mechanism of action, evidence 
suggests that statins have other important anti-inflammatory properties. The so 
called ‘pleiotropic’ effects of statins were highlighted in the conclusion of two 
large international trials (231, 232). These trials demonstrated beneficial effects 
of statin use after an acute coronary syndrome, which included a significant 
reduction of further plaque rupture events. One of the hypothesized explanations 
for this was an anti-inflammatory effect on the vulnerable plaque, supported by a 
decline in the inflammatory markers such as the C-reactive protein (CRP) in the 
statin treated group (233). My study did not include a measurement of the CRP 
and was underpowered to check the effects of statins on anti-inflammatory 
markers.  
It should be appreciated that there are subtle differences between the 
atherosclerotic processes in a transplant setting, compared to native coronary 
disease. This is evidenced by concentric rather than eccentric lesions, reduced 
lipid content and higher numbers of inflammatory cells in the transplant 
atherosclerotic lesion (234, 235). Whether or not statins have a different 
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magnitude of effect within each setting remains to be answered. My study would 
argue against any beneficial effect of statins on Tregs action in transplant 
atherosclerosis. Indeed, the results actually demonstrate a potentially detrimental 
effect on plaque burden, when the conclusions of a recent study by Warnecke 
and colleagues are taken into account (236). They demonstrated that Tregs were 
capable of reducing intimal occlusion in transplant atherosclerosis. They 
proposed this route of regression occurred via the regulation of effector CD4+ 
CD25- T cells by CD4+CD25+ T cells. Taking together, we can say that currently 
our knowledge remains limited about the mechanism of any potential 
immunoregulatory effects of statins within the atherosclerotic lesion.  
Although some of the patients in the Statin group were also taking 
Ezetimibe (a cholesterol lowering agent that acts by reducing cholesterol 
absorption in the intestine), this data was not included as part of the study. 
Hence, I was unable to detect any changes in Tregs due to Ezetimibe. None of 
the NOST group patient was taking Ezetimibe.  
Despite my findings however, statins remain beneficial to transplant 
patients and are proven to both prolong survival and reduce the development of 
coronary graft vasculopathy (237). This would suggest therefore that despite a 
negative effect on Tregs, there are other compensatory properties of statins 
existing that outweigh my findings, resulting in a net benefit to the patient. 
Further investigation into the immunomodulatory effects of statins would be 
beneficial to enhance our knowledge in this area and potential ability to treat 
vasculopathy more effectively. 
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Chapter 5 Chemotactic profile of T regulatory cells in a heart transplant 
cohort 
Abstract 
Background 
Tregs (CD4+CD25brightFOXP3+ T cells) are widely recognized as key 
elements in the transplant related tolerance. Following antigen stimulation, naïve 
Tregs change their phenotype, including a switch of their chemokine receptors. 
This critical step leads to the Treg migration to specific peripheral organs 
including secondary lymphoid tissue (SLT) or the allograft, etc. Various studies 
suggest specific chemotactic pathways guiding Tregs to inflammatory sites (71). 
However, there is lack of such data in humans following heart transplantation. 
Methods 
After thorough literature search, following chemokines were selected to 
detect chemotactic properties of peripheral blood Tregs in stable adult heart 
transplant recipients: CCL1, CCL2, CCL5, CCL17, CCL19, CCL21, CXCL9, 
and CXCL10. In-vitro chemotactic assays were performed for Tregs in 24 well 
insert systems (BD Falcon™) using 10 and 100 ng/ml solutions for each 
chemokine and compared against a negative control. Following the incubation, 
transfer of Treg to the lower chamber was assessed using flow cytometry. Direct 
comparison of migrated cell numbers and the “chemotactic index” (defined as 
the cells migrated in response to chemokine solution divided by the migrated 
cell count in negative control) was carried out. Demographic data and data on 
immunosuppressive medications were collected from the patient notes for risk 
stratification. All data was analyzed using SPSS v 15.  
Results 
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A total of 128 patient samples were used to carry out chemotactic assays using 
chemokines CCL5, CCL17, CCL19, CCL21, CXCL9, CXCL10 (n=18 each), 
and CCL1, CCL2 (n=10 each). I found that CCL17 and CCL5 caused dose-
dependent Treg specific migration (p<0.05). None of the other chemokines 
showed any specific Treg migration, while CD4+ lymphocytes without 
regulatory phenotype i.e. CD4+CD25- effector cells showed significant specific 
migration in response to CCL19 (p=0.04). 
Conclusion 
This study demonstrates for the first time a specific pattern of chemotaxis for 
Tregs in heart transplant patients. These results provide another avenue of 
research to determine therapeutic manipulations to guide circulating Tregs into 
the allograft. 
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Background 
Despite an improved overall survival, most of the heart transplant 
patients are administered a combination of two-three immunosuppressive 
medications to prevent acute and chronic rejection (184). These drugs have 
several undesirable side effects, including hypertension, renal failure, metabolic 
diseases, and tumours, which result in significant morbidity and mortality (238). 
Hence, induction of immunologic tolerance is highly desirable following 
transplantation. Tolerance denotes an ideal state of antigen-specific 
immunological unresponsiveness towards the allograft, thereby avoiding 
rejection and allowing sustained graft function without the need of 
immunosuppressive medications. A significant body of evidence suggests that 
immune regulation governed by T regulatory cells (Tregs) plays a key role for 
peripheral tolerance in both experimental and clinical transplantation models 
(30, 33, 34). The naturally occurring Tregs, first described by Sakaguchi et al 
(22) as CD4+CD25+ T cells, comprise 5-10 % of the peripheral blood CD4+ T 
cells in healthy adult humans and mice (35, 36). These cells have been reported 
to inhibit the proliferation of other CD4+ and CD8+ effector cells.  Due to 
similarities with effector T cells, functional characterization of Tregs has 
remained a challenge. However, it is now largely accepted that CD4+CD25bright 
cells expressing FOXP3 (a transcription factor) represent the Tregs (65). 
Immune regulation by Tregs is complex, involving non-specific cell-cell 
contact mechanisms as well as secretion of IL-10 and TGF-β (25, 29).  Hence, 
appropriate co-localization of Tregs with the effector cells is essential for Tregs 
to exert their regulatory function and control allo-reactivity (239). Indeed, like 
the effector T cells, Tregs require complex intra- and inter-compartmental 
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migration, from thymus to secondary lymphoid organs, and then to the 
peripheral tissues before recirculation (73, 240). This system is intricately 
controlled by a cohort of different chemokines and adhesion molecules. We 
postulated that transplantation may incur a difference in the dynamics of 
chemotaxis between CD4+CD25brightFOXP3+ Tregs and CD4+CD25-effector 
cells.  
With this background, I prospectively investigated the chemotactic 
properties of peripheral blood Tregs and the effector T cells in human heart 
transplant recipients. 
Methods 
Subjects and sample collection 
This was a prospective, observational, non-randomized study, conducted 
on stable (non-rejecting) adult heart transplant recipients attending the transplant 
outpatients department at the University Hospital of South Manchester. The 
exclusion criteria included evidence of acute rejection, acute infections, severe 
hepatic dysfunction, and inability to get an informed consent. Following 
informed consent, peripheral blood samples were collected from 71 participants. 
All the samples were collected in 5 ml EDTA (ethylenediamine-tetra-acetic 
acid) vacutainers, using standard venepuncture technique. According to our unit 
protocol, all patients were receiving combination of immunosuppression 
comprising cyclsopsorin or tacrolimus,  mycophenolic acid derivatives (MPA) 
or Azathioprine (Aza), and Prednisolone (Pred). Clinical and demographic data 
were collected from patient notes for risk stratification. 
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Isolation of peripheral blood mononuclear cells 
The blood samples were processed within 1-3 hours of collection and used to 
isolate peripheral blood mononuclear cells (PBMC) by density gradient 
centrifugation method using Ficoll-Paque as previously described (173). The 
cells were then suspended in RPMI-1640 medium (Sigma-Aldrich®), achieving 
up to 1-1.25 x 106 cells/ml. 
Chemokines and antibodies  
CCL1, CCL2, CCL5, CCL17, CCL19, CCL21, CXCL9, and CXCL10 
were purchased from ProSpec-Tany TechnoGene Ltd, Israel. Antibodies for 
surface molecules including anti-CD4 Phycoerythrin-Cy5 (PE-Cy5) and anti-
CD25 Phycoerythrin-Cy7 (PE-Cy7) were purchased from BD Biosciences, UK. 
Fluorescein isothiocyanate (FITC) conjugated anti-FOXP3 antibody was 
purchased from e-Bioscience, UK.  
Chemotaxis assays 
All the chemokines were diluted according to the required strength for 
chemotaxis, and aliquots were stored at -20ºC to avoid repeat freeze-thaw 
cycles. A carrier protein (0.1% bovine serum albumin) was added for long term 
storage. In-vitro cell migration assays were performed on PBMC using 8µm 
pore, 24 well insert system purchased from BD Falcon™. A 250µl of the cell 
suspension was added to the insert, while 750µl of chemokine solution in RPMI-
1640 was added to the lower well. A negative control was used for each patient, 
using 750µl of RPMI-1640 without chemokine in the lower well. The system 
was incubated for 4 hours at 37oC, 5% CO2 and normal humidity. Following 
incubation, transfer of Treg to the lower chamber was assessed using flow 
cytometry. Specific migration was calculated by direct measurement of Treg 
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numbers in the chemokine versus control solution. Chemotactic index for each 
chemokine was calculated as a ratio of the Treg counts migrated in response to 
the chemokine solution and those in the control medium. Similar calculations 
were carried out for CD4+CD25- effector cells. 
Treg immunophenotyping 
The cell suspension from the lower well of the HTS multi-well system 
was extracted into a 5 ml polypropylene tube, washed with PBS (phosphate 
buffered saline) at room temperature, and then centrifuged at 1500 rpm for 10 
minutes. The cell pellet thus created was stained with anti-CD4 PE-Cy5 and 
anti-CD25 PE-Cy7 for 30 minutes in the dark at 4oC (to avoid denaturing by UV 
light), followed by intracellular staining with FITC conjugated anti-human 
FOXP3 using fixation/ permeabilization solutions according to the 
manufacturers guidelines. Isotype controls using mouse antibodies were 
included to provide a negative cell reference.  
Flow cytometry 
I used BD™ LSR II flow cytometer with linear forward scatter (FSc), 
linear side scatter (SSc), and log fluorescence 1 (FL1), 2 (FL2) and 3 (FL3) 
detection. A standard FS/SS lymphocyte gating strategy was used along with 
bright and dim gating strategy using FACSDiva™ software. Data was collected 
for either a maximum of 300 seconds or ten thousand events for all antibody 
combinations and was analyzed using EXPO32 ADC Analysis software 
(Beckman Coulter). 
Statistical analysis 
For statistical comparisons and clinical correlations, data analysis was 
performed using SPSS v15. Intergroup comparisons were made using t-test or 
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Mann Whitney U test, depending on the normality of distribution. Comparisons 
between multiple chemokine groups were made using one-way ANOVA. Dose 
response was evaluated using generalized linear model. A p value of < 0.05 was 
considered statistically significant.  
Results 
A total of 128 chemotaxis assays were carried out with PBMC from 71 
adult heart transplant patients. Tregs (CD4+CD25brightFOXP3+) comprised a 
small fraction of the CD4+ population (median 0.5, range 0-6.7), while the 
CD4+CD25- effector cells comprised 66.4 % (±19.2) of the CD4 cells. Rest of 
the CD4+ cells belonged to the CD4+25dim group which were not assessed. Due 
to the small numbers of peripheral Tregs it was not possible to perform 
simultaneous chemotaxis for all the selected chemokines on each patient. 
However, inter-group comparisons of the clinical and demographic data were 
performed for risk stratification. There was a significant difference between the 
groups in terms of age (p=0.029), with CCL2 group being the youngest at a 
mean age of 47.5 (±15.4). However, I found no other differences between the 
groups in terms of demographics or immunosuppression (table 5.1-5.3).  
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Table 5.1 Demographics for the various groups of chemokines as shown 
in the first column. Age and duration since transplant are expressed in mean 
(standard deviation). eGFR = estimated glomerular filtration rate, vMDRD (4 
variable Modification of Diet in Renal Disease formula).   
Group Age Sex 
(% 
male) 
Duration 
since Tx 
(days) 
Diabetes 
(%) 
Hypertens
ion (%) 
eGFR 
(vMDRD, 
ml/min) 
CCL1 
(n=10) 
60.1 
(8.25) 
100 2372.1 
(1951.05) 
30.0 100 49.7 (16.41) 
CCL2 
(n=10) 
47.5 
(15.47) 
70 3270.2 
(2636.18) 
30.0 80.0 41.6 (22.87) 
CCL5 
(n=18) 
60.44 
(7.22) 
94.4 3222.06 
(2102.35) 
50.0 94.4 38.06 (12.63) 
CCL17 
(n=18) 
50.94 
(15.79) 
83.3 3709.94 
(2228.83) 
22.2 88.9 45.06 (18.15) 
CCL19 
(n=18) 
51.61 
(12.47) 
72.2 2732.5 
(2220.04) 
22.2 94.4 44.11 (17.38) 
CCL21 
(n=18) 
57.44 
(9.25) 
94.4 2763.94 
(1724.06) 
22.2 100 45.61 (13.8) 
CXCL19 
(n=18) 
56.5 
(8.54) 
83.3 3933.56 
(2472.57) 
33.3 83.3 35.83 (16.61) 
CXCL10 
(n=18) 
55.0 
(9.43) 
83.3 3994.78 
(2523.81) 
33.3 83.3 35.83 (18.04) 
P value 0.029 0.28 0.36 0.64 0.41 0.23 
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Table 5.2 Immunosuppressive and immunomodulatory drugs used for 
the various chemokine groups. (Pred dose in mean (standard deviation) 
(Cyclo=cyclosporin, FK=tacrolimus, Aza=azathioprine, MMF=mycophenolate 
mofetil, Pred= prednisolone, ACEi = Angiotensin converting enzyme inhibitors) 
 
Chemokine 
Group 
Cyclo/FK 
(% on 
Cyclo) 
Aza/MMF 
(% on 
MMF) 
Pred 
dose 
(mg/day) 
Beta 
blockers 
(%) 
ACEi 
(%) 
Statin 
(%) 
CCL1 100 70.0 7.75 
(2.18) 
10 80 100 
CCL2 70.0 50.0 5.50 
(4.83) 
0 60 70 
CCL5 94.1 72.2 7.20 
(2.77) 
23.5 64.7 88.2 
CCL17 94.4 50.0 5.97 
(4.21) 
27.8 61.1 83.3 
CCL19 83.3 66.7 5.55 
(4.33) 
11.1 61.1 83.3 
CCL21 83.3 72.2 7.63 
(3.87) 
33.3 72.2 88.9 
CXCL19 94.4 61.1 5.69 
(4.68) 
33.3 72.2 77.8 
CXCL10 94.4 61.1 4.72 
(4.84) 
44.4 72.2 77.8 
P value 0.279 0.94 0.34 0.12 0.94 0.68 
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Table 5.3 Peripheral blood cell counts for the different groups of 
chemokines measured at the time of sampling for the chemotaxis assays.  
All cell counts in x109/L.  *mean ± standard deviation, rest of the data is 
expressed in median (25th, 75th percentile) (WBC: white blood cells, Neutro: 
neutrophils, Lympho: lymphocytes, Mono: monocyte, Eosino: eosinophils.) 
 
Group WBC Neutro Lymp
ho 
Mono Eosino Basop
hil 
Platelet 
CCL1 *7.72 
(2.50) 
*5.91 
(2.32) 
0.9 
(0.29, 
3.32) 
0.64 
(0.34, 
0.89) 
0.05 
(0.01, 
0.3) 
0.05 
(0.01, 
0.3) 
232.17 
(27.23) 
CCL2 *6.81 
(3.23) 
*4.91 
(2.65) 
1.11 
(0.2, 
2.04) 
0.66 
(0.09, 
1.06) 
0.1 
(0.01, 
0.21) 
0.02 
(0.01, 
0.03) 
302.7 
(86.68) 
CCL5 *7.6 
(1.92) 
*5.63 
(1.83) 
0.94 
(0.34, 
3.0) 
0.64 
(0.3, 
1.08)  
0.08 
(0.0, 
0.33) 
0.01 
(0.0, 
0.08) 
247.99 
(59.81) 
CCL17 *7.43 
(1.73) 
*5.14 
(1.51) 
1.43 
(0.57, 
3.32)  
0.6 
(0.45, 
1.26) 
0.08 
(0.03, 
0.27) 
0.02 
(0.01, 
0.05) 
253.16 
(70.54) 
CCL19 *6.45 
(1.57) 
*4.37 
(1.51) 
1.1 
(0.75, 
3.34) 
0.64 
(0.28, 
1.0) 
0.06 (0, 
0.17) 
0.01 
(0.0, 
0.04) 
265.66 
(54.50) 
CCL21 *7.91 
(2.12) 
*5.74 
(1.79) 
1.1 
(0.71, 
3.32) 
0.66 
(0.37, 
1.27) 
0.08 
(0.02, 
0.3) 
0.02 
(0.01, 
0.05) 
253.50 
(75.91) 
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Continued Table 5.3 
Group WBC Neutro Lympho Mono Eosino Basophil Platelet 
CXCL19 6.81 
(1.56) 
4.72 
(1.40) 
1.13 
(0.57, 
3.0) 
0.61 
(0.28, 
1.08) 
0.09 
(0.0, 
0.33) 
0.02 
(0.0, 
0.08) 
244.61 
(45.46) 
CXCL10 6.36 
(1.58) 
4.46 
(1.54) 
1.09 
(0.55, 
1.90) 
0.58 
(0.28, 
1.0) 
0.11 
(0.0, 
0.27) 
0.02 
(0.0, 
0.06) 
240.50 
(49.05) 
P value 0.16 0.10 0.24 0.86 0.70 0.56 0.24 
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Tregs show specific migration in response to CCL17 and CCL5 
Amongst the homeostatic chemokines, peripheral blood Tregs showed 
specific migration to CCL17, with a significant dose-response curve (p=0.03) 
(Fig 5.1 and 5.2). In terms of the inflammatory chemokines, only CCL5 caused 
specific Treg chemotaxis (p=0.04), as shown in Fig 5.3 and 5.4. I did not find 
any statistically significant chemotaxis of Tregs in response to CCL1, CCL2, 
CCL19, CCL21, CXCL9, or CXCL10 (Fig 5.5 and 5.6) 
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Fig 5.1  Box plot showing in-vitro Treg migration in response to the 
two different strengths of CCL17 (10 and 100 ng/ml) compared to a 
negative control (no chemokine) (on the x-axis). The results represent a mean 
of 18 assays for each of the chemokine solutions. The y-axis represents the Treg 
counts.  
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Fig 5.2  Graph showing dose-dependent in-vitro migration of Tregs in 
response to CCL17. The x-axis shows the two different concentrations of 
CCL17 (10 ng/ml and 100 ng/ml), and the control (no chemokine). The y-axis 
shows the logarithmic means of Tregs for each set of chemokine strength (mean 
of 18 assays for each group).  
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Fig 5.3  Box plot showing in-vitro Treg migration in response to the 
two different strengths of CCL5 (10 and 100 ng/ml) compared to a negative 
control (no chemokine) (on the x-axis). The results represent a mean of 18 
assays for each of the chemokine solutions. The y-axis represents the Treg 
counts.  
 
contro l CCL5 10 CCL5 100
Chemotaxis with CCL5
0.00
10.00
20.00
30.00
40.00
50.00
Tr
eg
 
co
u
n
t
S
 
 
 
 
 
 
 
 
 141 
 
Fig 5.4  Graph for the result of in-vitro chemotaxis assay showing 
dose-dependent migration of Tregs in response to CCL5. The x-axis 
represents the two different concentrations of CCL5 (10 ng/ml and 100 ng/ml) 
compared against the control (no chemokine), while the y-axis shows the 
logarithmic means of Treg counts (mean of 18 assays for each group).  
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Fig 5.5  Box plots showing in-vitro Treg migration in response to 
CCL1 (5.5a), CCL2 (5.5b), CCL19 (5.5c) and CCL21 (5.5d). The x-axis 
shows the two different concentrations of the chemokines (10 ng/ml and 100 
ng/ml), and the control (no chemokine). The y-axis represents the Treg counts. 
The results represent a mean of 10 assays for CCL1 and CCL2, and mean of 18 
assays for CCL19 and CCL21 solutions. 
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Fig 5.6  Box plots showing in-vitro Treg migration in response to 
CXCL9 (5.6a) and CXCL10 (5.6 b). The x-axis shows the two different 
concentrations of the chemokines (10 ng/ml and 100 ng/ml), and the control (no 
chemokine). The y-axis represents the Treg counts. The results represent a mean 
of 18 assays for each chemokine solutions. 
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Tregs possess different chemotaxis properties compared to effector cells 
I then looked at the chemotactic profile of CD4+CD25- effector cells. 
These cells did not show the same pattern of chemotaxis as Tregs; instead the 
effector cells were found to be migrating more specifically in response to 
CCL19. There was no significant chemotaxis of these cells with any of the other 
chemokines. (Fig 5.7-5.9) 
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Fig 5.7  Graph showing dose-dependent in-vitro chemotaxis of 
CD4+CD25- lymphocytes in response to CCL19. The x-axis represents the two 
different concentrations of CCL19 (10 ng/ml and 100 ng/ml) compared against 
the control (no chemokine), while the y-axis shows the CD4+CD25- counts 
(mean of 18 assays for each group). 
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Fig 5.8: Box plots showing in-vitro chemotaxis of CD4+CD25- lymphocytes in 
response to CCL1 (5.8a), CCL2 (5.8b), CCL5 (5.8c) and CCL17 (5.8d). The x-
axis shows the two different concentrations of the chemokines (10 ng/ml and 100 
ng/ml), and the control (no chemokine). The y-axis represents the CD4+CD25- 
counts. The results represent a mean of 10 assays for CCL1 and CCL2, and mean 
of 18 assays for CCL19 and CCL21 solutions. 
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Fig 5.9: Box plots showing in-vitro chemotaxis of CD4+CD25- lymphocytes in 
response to CCL19 (5.9a), CCL21 (5.9b), CXCL9 (5.9c) and CXCL10 (5.9d). 
The x-axis shows the two different concentrations of the chemokines (10 ng/ml 
and 100 ng/ml), and the control (no chemokine). The y-axis represents the 
CD4+CD25- counts. The results represent a mean of 18 assays for each solution.  
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Chemotactic index of Treg versus effector cells 
Having seen a difference in the overall cell migration in response to 
different chemokines, I compared the difference in chemotactic response of 
Tregs versus the effector cells under same dose of chemokines. CCL19 showed 
significant specificity for CD4+CD25- effector cells, while there was no 
statistically significant difference in the chemotactic indices for Tregs or the 
effector cells for other chemokines (Fig 5.10, 5.11) 
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Fig 5.10 Chemotactic indices for Tregs and CD4+CD25- lymphocytes 
in response to CCL1 (5.10a), CCL2 (5.10b), CCL5 (5.10c) and CCL17 
(5.10d). The blue lines represent the Tregs, while the green lines represent the 
CD4+CD25- lymphocytes. The results represent mean of 10 experiments for 
CCL1 and CCL2, and mean of 18 experiments for CCL5 and CCL17. 
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Fig 5.11 Chemotactic indices for Tregs and CD4+CD25- lymphocytes 
in response to CCL19 (5.11a), CCL21 (5.11b), CXCL9 (5.11c) and CXCL10 
(5.11d). The blue lines represent the Tregs, while the green lines represent the 
CD4+CD25- lymphocytes. The results represent mean of 18 experiments for each 
assay. 
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Discussion 
This study demonstrates for the first time that the peripheral blood 
FOXP3+ Tregs in heart transplant recipients possesses specific chemotactic 
response profile different from the conventional effector lymphocytes. It 
provides an important insight of the potential differences in Tregs and effector 
cell mobilization within the body, with consequences for allogeneic immune 
response.  
Like the effector T cells, Tregs require effective in-vivo mobilization 
between thymus, lymphoid tissue and the allograft in order to execute optimum 
regulatory function. However, Tregs possess slightly different chemokine 
receptor profile even at the precursor stage in thymus; CXCR4 is expressed by 
more FoxP3+ cells than FoxP3- cell, while the reverse is true for CCR9 
expression (141). Following transplantation, Tregs are stimulated via TCR 
activation, through either direct or indirect allo-recognition pathways. This 
antigen priming happens in the SLT and leads to an overhaul of chemokine 
receptors on Tregs; from CCR7 to effector-memory-like chemokine receptors 
including CCR2, CCR4, CCR6, CCR8 and CCR9 (141). Iellem et al showed 
that peripheral blood Tregs in healthy individuals exhibit greater selective 
expression of CCR8 (p=0.0001) and CCR4 (p=0.03) than CD4+CD25- cells. 
Their in-vitro chemotaxis assays demonstrated a significantly greater (p <0.01) 
migration of Tregs compared to CD25- T cells in response to CCL17 and CCL22 
(CCR4 ligands) and, CCL1 (CCR8 ligand), plus a synergistic effect of the 
suboptimal doses of CCL1 and CCL22 (37). My findings were different from 
this study, since I found significant in-vitro chemotaxis in response to CCL17 
(CCR4 ligand), but not to CCL1.  
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CCL17 is secreted by several inflammatory cells, including antigen 
presenting dendritic cells, and monocytes (241). This chemokine probably plays 
an important role in recruiting Tregs to antigen presenting cells and the area of 
inflammation. The importance of CCL17 / CCR4 axis is particularly highlighted 
in several studies on cancer patients. Ishida et al showed that Hodgkin’s 
Lymphoma cells produce CCL17 to attract Tregs via CCR4, so as to evade host 
immune defence by suppressing anti-tumour reactive lymphocytes (242). The 
clinical relevance was provided in the study by Curiel et al, who showed that 
specific migration of CCR4+ Tregs to the tumour tissue provides immune 
privilege and is associated with poor survival (71). Another study on patients 
with neoplastic meningitis demonstrates similar “tumour-protective” specific 
recruitment of Tregs (243).  
In transplant setting, there is evidence to suggest that the specific Treg 
recruitment via CCR4 and its ligands is essential for tolerance. In a murine 
model of induced allo-tolerance via CD154mAb and donor specific transfusion 
(DST), tolerance was associated with an infiltration of Tregs in the allograft. 
The same study also showed that CCR4-/- mice rejected the allograft associated 
with reduced infiltration of Tregs, however, the number and function of 
peripheral Tregs were normal. Hence, this study suggested that CCR4 ligands do 
not impact on Tregs development, but play a key role in Tregs migration to the 
allograft (143). In another fully mismatch murine cardiac transplant model with 
induced tolerance, Ochando et al showed that alloantigen-bearing plasmacytoid 
DC migrate to lymph nodes and affected allospecific Treg development via the 
CCR4 / CCL17 pathway. The same protocol in CCR4-/- mice prevented failure 
of Tregs development, leading to rejection (144). 
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CCL5 is the ligand for the chemokine receptor CCR5 that has been 
associated with pro-inflammatory cellular infiltration in acute and chronic 
allograft rejection (102, 164). A study on mice showed that approximately 20% 
of Tregs in murine SLT constitutively express CCR5 and immune activation 
leads to enhanced expression of both CCR5 and Foxp3. The same study revealed 
that CCR5 related pathway caused preferential accumulation of Tregs in the 
gravid uterus for tolerance induction (168). Kang et al demonstrated in a murine 
model of chronic inflamed intestine that CCR5 / CCL5 pathway was 
preferentially used by Foxp3+ Tregs for homing to the inflamed tissues. 
Interestingly, activated CD8+ T cells were the major source of the secreted 
CCL5, suggesting a possible role of CCL5 in balancing the effector and 
regulatory response. It was demonstrated that in vitro activation caused 
significantly more Foxp3+ cells than Foxp3- cells to express CCR5, and their 
migration was blocked by TAK-779, a CCR5 antagonist (169). Another study in 
murine model of acute graft-versus-host disease reported that Tregs used CCR5-
related pathways for homing to the target organs, and this migration was 
essential for suppression of the effector response. The investigators did not 
mention the chemokines involved in this migration (171). My results show that 
in clinically stable heart transplant recipients, CCL5 can cause significant in-
vitro migration of FOP3+ Tregs. This suggests that CCL5 / CCR5 axis may play 
an important role in allograft immune homeostasis.  
CXCR3 ligands CXCL9 and CXCL10 are often associated with acute 
allograft rejection, but it is uncertain if they play a role in Treg trafficking (89, 
90). Under homeostatic conditions Tregs express low levels of CXCR3, and 
show minimal chemotactic response to the three inflammatory CXC chemokines 
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(37). My study demonstrates a similar pattern, with a non-significant migration 
of Tregs in response to CXCL9 and CXCL10 under stable conditions. The 
expression of CXCR3 probably increases during the stress response of 
inflammation or rejection following transplantation. An evidence was provided 
by Eksteen et al demonstrated the presence of CXCR3high Tregs around inflamed 
bile ducts in chronically inflamed human liver (72). In another study involving 
murine model of experimental autoimmune encephalomyelitis, CXCR3 
expression was associated with infiltration of Tregs and containment of the 
tissue damage (149).  
Recognition of the specific chemotactic profile of effector cells and 
Tregs may help in developing novel strategies for tolerance induction. For 
example, I found that in contrast to Tregs, the effector T cells showed specific 
migration in response to CCL19. This is a homeostatic chemokine, secreted at 
the high endothelial venules and fibroblastic reticular cells within T cell zones of 
the SLT and is responsible for T cell homing to the SLT (124). It is therefore 
important for the induction of alloresponse, and one can speculate that blocking 
this chemokine may have a role in preventing rejection without affecting Tregs. 
In fact, a study using the experimental models of kidney and heart 
transplantation showed by blocking CCR7 (CCL19 ligand) that allospecific 
effector T cell proliferation was reduced and the allograft survival was 
significantly prolonged from 9 days to 20 weeks (131). Such work paves way 
for exciting new avenues for future studies, which may involve either blocking 
or alteration of chemokine expression via immunomodulatory drugs and genetic 
modifications. 
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In conclusion, my limited observational study shows a difference in the 
dynamics of chemotaxis between the Tregs and effector cells in stable heart 
transplant recipients. Further work may demonstrate relevance during states of 
acute and chronic rejection. 
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Chapter 6        Role of CCL17 in Treg migration following heart 
transplantation 
Abstract 
Background 
FOXP3+ T regulatory cells (Tregs) possess suppressive properties against 
alloreactive effector cells and are considered pivotal in tolerance induction 
following transplantation. Tregs migrate to the allograft under influence of 
certain chemotactic cytokines. My previous data on in-vitro chemotaxis suggests 
that peripheral blood Tregs specifically migrate in response to the chemokine 
CCL17. However, it is uncertain if CCL17 has a role for in-vivo migration of 
Tregs to the allograft.  
Methods 
In this observational study, double immunofluorescence labelling was 
performed to identify CD4+FOXP3+ Tregs in 12 endomyocardial biopsies from 
4 adult heart transplant recipients. The rejection grade was identified by expert 
histopathologists according to the International Society of Heart and Lung 
Transplantation (ISHLT) criteria. Further immunostaining was performed on 
sequential cuts from the same samples to detect CCL17 expression that was 
correlated with the Treg and effector cell infiltration. Demographic and 
immunosuppression data was collected from patient records. Data was analyzed 
using SPSS v15. 
Results 
Acute rejection was present in 4 out of 12 biopsies (33.3%). CD4+ 
FOXP3- effector cells were present in both rejecting and non-rejecting samples; 
however, CD4+FOXP3+Tregs were identified in the rejecting samples only. 
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Although there was no statistically significant rise in CCL17 expression during 
the rejecting state, the CCL17 expression pattern was significantly correlated 
with both CD4+ FOXP3- effector (p=0.02) and CD4+FOXP3+ Treg counts 
(p<0.01) in the rejecting samples.  
Conclusion 
This study demonstrated that CCL17 is associated with CD4+FOXP3- 
cells and Treg infiltration during acute rejection following heart transplantation. 
Tregs increase in number in the allograft during acute rejection, and that CCL17 
secretion may be responsible for Treg migration to the allograft. This finding 
may have important implications, since Tregs play pivotal roles in the 
alloresponse and their selective migration can be utilized as a tool for tolerance 
induction following transplantation. 
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Background 
Transplantation leads to an activation of the allospecific immune 
response causing infiltration of mononuclear cells into the allograft, which is the 
hallmark of acute rejection (186). At the same time, however, there occurs an 
activation of a special subset of T cells, called T regulatory cells (Tregs) that are 
capable of suppressing the allo-specific immune response leading to a state of 
immune privilege known as peripheral tolerance (30, 34). Initially described as 
important for maintaining tolerance against self antigens (22), the role of Tregs 
in transplant-related tolerance is now widely acknowledged (33, 244, 245).  
Tregs have been identified as a small subset (approximately 5-10%) of the 
peripheral blood CD4+ T cells, expressing high levels of cell surface CD25 and 
the transcription factor FOXP3 (35, 65, 246). It appears that the level of FOXP3 
expression is directly related to the regulatory potential of Tregs (247). Its 
deletion or mutations lead to a variety of autoimmune diseases in both animals 
and humans (248), while retroviral transfer to naïve T cells renders them the 
regulatory profile (249).   
Naturally occurring Tregs are generated in thymus. Subsequently they 
migrate to the secondary lymphoid tissue (SLT) where they get activated via 
TCR stimulation (250). Further migration of allo-specific Tregs to the site of 
antigenic challenge is the key step towards suppression of effector response 
(251). This is due to the fact that Tregs function via local secretion of cytokines 
or cell-cell contact dependent mechanism (25, 239). 
Chemokines are small chemotactic proteins secreted by various cells to 
facilitate leucocyte migration towards specific sites of interest (81). The 
chemokines bind to seven-pass, trans-membrane-spanning serpentine, Gi/Go protein-
 159 
coupled, Bordetella pertussis toxin-sensitive receptors. Approximately 50 chemokines 
and 20 chemokine receptors have been identified in humans and mice (82). Evidence 
suggests that different subsets of lymphocytes including Tregs show unique 
chemotactic response profiles during homeostasis, inflammation and following 
transplantation (73, 252, 253). In this context, CCL17 (also known as Thymus 
and Activation Regulated Chemokine or TARC) appear to cause Treg specific 
migration in healthy individuals and certain cancers (37, 242, 254). There is 
evidence to suggest that Tregs specifically migrate to the allograft in human 
heart transplant recipients (255). However, the specific chemokine signal 
responsible for this Treg migration to the allograft is yet to be established.  
My previous experiment on in-vitro chemotaxis in stable heart transplant 
recipients shows that CCL17 causes specific migration of peripheral blood 
Tregs. Hence, I postulated that CCL17 may be responsible for in-vivo migration 
of Tregs following heart transplantation. 
Methods 
This was a retrospective, observational, non-randomized study conducted 
on the adult human heart transplant recipients. The study was designed to 
correlate the pattern of CCL17 expression with Treg infiltration in three serial 
endomyocardial biopsies from each patient, including a biopsy with no rejection 
(Biopsy 1), followed by a biopsy showing at least moderate rejection (Biopsy 2), 
followed by another biopsy with no rejection (Biopsy 3). To fulfil this criterion, 
I could only identify 4 heart transplant recipients who had biopsies from April 
2008 till March 2009, and showed at least moderate degree of rejection in one 
biopsy. Hence, the study could not be sufficiently powered to detect minor effect 
size. The 12 formalin-fixed, paraffin embedded endomyocardial biopsy 
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specimens were then obtained following informed consent. The biopsies were 
performed by the clinical team responsible for the patients according to the local 
guidelines and were graded for rejection according to the revised ISHLT criteria 
(180). As mentioned earlier, 4 samples had evidence of acute cellular rejection 
on routine H&E staining, while 8 samples had no rejection. Clinical and 
demographic data including the use of immunosuppressive agents (Prednisolone 
(Pred), Cyclosporine (Cyclo), Tacrolimus (FK), Mycophenolate Mofetil (MMF) 
and Azathioprine (Aza) administration) and haematological white blood cell 
counts (neutrophils, lymphocytes, monocytes, eosinophils, basophils and 
platelets) were collected from patient records. The study was approved by the 
local ethics committee.  
Immunofluorescence labelling for Tregs 
All the samples were serially sectioned to 4µm thickness using the 
standard microtome. The sections were deparaffinised and rehydrated in graded 
alcohol before heat-induced antigen retrieval in a pressure cooker using Citrate 
buffer (pH 6.0) as previously described. Following incubation with 10% normal 
donkey serum to block non-specific staining, the sections were labelled with 
monoclonal mouse anti-human CD4 (1:50 dilution, clone BC/1F6, Abcam®, 
UK) overnight at 4ºC followed by Alexa Fluor® 555 donkey anti-mouse IgG 
(H+L) (Invitrogen®, UK) for 1 hour. This was followed by second staining 
sequence, which again started with 10% donkey serum for 1 hour, then rat anti-
human FOXP3 (1:50 dilution, clone PCH101, eBioscience, UK) overnight at 
4ºC followed by Alexa Fluor® 488 donkey anti-rat IgG (H+L) (Invitrogen®, 
UK) for 1 hour. Due to high background auto fluorescence, sections were 
incubated with 0.5% Sudan black for 10 minutes before nuclear counterstaining 
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with DAPI (4', 6-diamidino-2-phenylindole dilactate; 1:10,000, Biotium, CA). 
The sections were then mounted with Prolong Gold® anti-fade reagent 
(Molecular Probes®, OR). The entire sections were evaluated using 
epifluorescent microscope (Olympus® BX51, Japan) and images acquired using 
CoolSNAPHQ Monochrome camera (Roper Scientific®, AZ) with MetaVue™ 
Imaging System (Molecular Devices®, PA) (Fig 6.1). CD4+FOXP3- and 
CD4+FOXP3+ cells (Tregs) were counted in at least 5 non-overlapping high 
power fields (x60). Tonsil tissue was used as the positive control, while primary 
antibodies were omitted for a negative control. 
Immunohistochemistry for CCL17  
Sequential 4µm cuts from the 12 FFPE endomyocardial samples selected 
earlier were stained with polyclonal rabbit anti-human CCL17 (1:800, 
AHP1919, AbD Serotec®, Oxford, UK). I used ImmPRESS™ peroxidase 
detection system (Vector® labs, CA) to detect CCL17 in the samples. In short, 
after deparaffinization in xylene and rehydration in graded alcohol, the sections 
were subjected to heat-induced antigen retrieval using citrate buffer (pH 6.0). 
The endogenous peroxidise activity was quenched by incubation in 0.3% 
hydrogen peroxide solution in alcohol. Following blockade with 2.5% normal 
horse serum the sections were stained with the anti-CCL17 antibody for 30 
minutes each. Further 30 minutes incubation was performed with ImPRESS™ 
reagent before application of ImmPACT™ DAB (diaminobenzidine) (Vector® 
labs, CA) for 5 minutes. Nuclear counter stain was performed with 
Haematoxylin and mounted using DPX resin (Fig 6.2). Once again, tonsil tissue 
was used as the positive control. The primary antibody was excluded for the 
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negative control. The degree of staining was assessed and quantified on a scale 
of 0-3 by two expert histopathologists at our Pathology department.  
Statistical analysis 
The data was tabulated using excel and analyzed with SPSS v15. Paired 
analysis was performed to compare the demographic, clinical and staining data 
for the three biopsy time points. Data with normal distribution was assessed with 
paired sample t test or the one way ANOVA, while non-parametric data were 
assessed by Mann-Whitney U test or the Friedman one-way repeated measures 
analysis of variance by ranks. Analysis of correlations between CD4+FOXP3- 
cells, CD4+FOXP3+ cells, and CCL17 expression were performed by 
Spearman’s rank correlation test. A two-sided p value <0.05 conferred statistical 
significance.  
Results 
All patients were males, with a mean age of 40.4 (±14.4) years. The 
median duration of the three serial biopsies since transplant were 217.5 (68.2, 
633.0), 313.0 (118.5, 993.5), 349.5 (140.0, 1085.5) days respectively. There was 
no significant difference between rejecting versus non-rejecting states in terms 
of immunosuppression, immunomodulatory drugs (including statins), or renal 
dysfunction (table 6.1). At the time of the first and second biopsies, all patients 
were taking Cyclo only, however 2 patients were switched to FK by the time of 
their third biopsy. In terms of MMF and Aza, only one patient was on Aza when 
he had his first biopsy, while the others were taking MMF. Subsequently, all 
patients were receiving MMF. The median prednisolone doses were 10.0 mg 
(10.0, 21.25), 8.7 mg (7.5, 21.25), and 11.0 mg (8.12, 21.75) respectively at the 
time of the three serial biopsies (p=0.36). Table 6.1 summarizes the differences 
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in estimated glomerular filtration rate (eGFR) and peripheral blood counts at the 
times of serial biopsies. 
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Table 6.1 Renal function and peripheral blood cell counts at serial 
biopsy time points.  
All data in mean (SD). Biopsy1, 2 and 3 correspond to the three serial 
endomyocaridal biopsies performed in four subjects. (eGFR = estimated 
glomerular filtration rate, WBC = White blood cells) 
 Biopsy #1 Biopsy #2 Biopsy #3 P 
value 
eGFR 
(ml/min) 
67.0 (24.89) 52.0 (24.75) 47.25 (26.6) 0.21 
WBC (x109/l) 10.1 (2.39) 8.37 (1.93) 11.07 (4.18) 0.52 
Neutrophils 
(x109/l) 
8.18 (1.92) 7.28 (1.66) 8.34 (3.19) 0.26 
Lymphocytes 
(x109/l) 
1.14 (0.8) 1.05 (0.8) 1.79 (1.1) 0.18 
Monocytes 
(x109/l) 
0.67 (0.37) 0.5 (0.18) 0.8 (0.23) 0.54 
Eosinophils 
(x109/l) 
0.08 (0.1) 0.12 (0.1) 0.09 (0.3) 0.89 
Basophils 
(x109/l) 
0.015 (0.01) 0.03 (0.03) 0.025 (0.02) 0.51 
Platelets 
(x109/l) 
265.5 (79.38) 235.75 (71.92) 243.75 (108.11) 0.26 
 
 
 
 
 
 
 
 
 
 
 165 
Fig 6.1  Double immunofluorescence labelling of Tregs with CD4 and 
FOXP3 antibodies in a representative endomyocardial biopsy.  
Blue staining denotes nuclear counter-stain with DAPI (4', 6-diamidino-2-
phenylindole, dilactate). CD4 stain was seen with red (Cy3) filter staining the 
membrane (red arrows), while the white arrow points to intranuclear FOXP3 
staining (green with FITC filter). 
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Fig 6.2  Immunoperoxidase staining of a representative section of the 
formalin-fixed, paraffin embedded endomyocaridal biopsy showing CCL17 
staining within the lymphocytic infiltrate.  
White arrow points to CCL17 staining, while black arrow points to a 
lymphocyte. Myocardial nuclei are stained blue with haematoxylin (x100 
magnification).   
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Tregs versus CD4+FOXP3- effector cells in the endomyocardial biopsy 
Out of a total of twelve biopsy samples, CD4+FOXP3- cell infiltration 
was identified in 2 rejecting (median count 6.0 (0, 27.75) and 2 non-rejecting 
(median count 2 (0, 24.25) samples. One patient had CD4+FOXP3- cell 
infiltration in both non-rejecting (Biopsy 1) and rejecting (Biopsy 2) samples. 
The other two samples belonged to one rejecting and one non-rejecting patient. 
Interestingly, no CD4+ cells were observed in the third series of biopsies (Biopsy 
3).  
Despite the presence of CD4+FOXP3- cells in the non-rejecting samples, 
FOXP3+ Tregs were identified in two rejecting samples only, comprising 6.45% 
(0, 21.97%) of the CD4+ cell counts. I found no significant association between 
CD4+FOXP3- counts or Tregs and the demographic data.  
Changes in CCL17 expression during acute rejection 
In the next step, the sequential staining pattern of CCL17 was compared 
during the acute rejection and non-rejecting states. While there was an enhanced 
staining of CCL17 in samples with acute rejection, I did not find a statistically 
significant difference compared to the non-rejecting samples (Fig 6.3). 
Association of CD4+ FOXP3- cells and Tregs with CCL17  
In the samples with acute rejection (Biopsy 2), both CD4+FOXP3- and 
Treg counts were significantly associated with the degree of CCL17 staining 
(p=0.02 for CD4+FOXP3- and p<0.01 for Tregs) (Fig 6.4, and 6.5).  
Due to the small numbers of Tregs, I wanted to check if Treg: CD4+ ratio 
was associated with CCL17 expression. However, I found no significant 
association between Treg: CD4+ ratio and CCL17 (p=0.22). There was also no 
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association between CD4+ counts and CCL17 expression in the non-rejecting 
samples. 
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Fig 6.3  Graph showing mean CCL17 expression in serial 
endomyocardial biopsies in non-rejecting, rejecting, and then non-rejecting 
states. Each point refers to a mean of 4 samples.  
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Fig 6.4  Graph showing CD4+FOXP3- lymphocyte counts (y axis) 
versus CCL17 expression (x axis) in the rejecting endomyocardial biopsy 
tissues (n=4). P value denotes the two-tailed significance value from 
Spearman’s correlation (r=Spearman’s correlation coefficient). 
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Fig 6.5  Graph showing Treg counts (y axis) versus CCL17 expression 
(x axis) in the rejecting endomyocardial biopsy tissues (n=4). P value denotes 
the two-tailed significance value from Spearman’s correlation (r= Spearman’s 
correlation coefficient). . 
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Discussion 
To my knowledge, this is the first study to assess the correlation of 
intragraft CCL17 with in-vivo allograft migration of FOXP3+ Tregs following 
clinical heart transplantation. Herein I demonstrated a significant association 
between CCL17 staining and infiltration of CD4+FOXP3- and Treg lymphocytes 
in the allograft during acute rejection.  
Within the past couple of decades Tregs have increasingly been realized 
to have an important role in peripheral tolerance against self and allo-antigen (6, 
22, 33). Consistent with these findings, experimental studies show that 
therapeutic use of ex-vivo expanded Tregs prevents allograft rejection and 
perhaps induces state of tolerance (66). In humans, heart transplantation has seen 
improved outcome in recent years owing to provision of better 
immunosuppression, which unfortunately leads to several other side effects 
(184). At the same time, the incidence of chronic rejection remains high (256). 
Hence, induction of peripheral tolerance is highly desirable, and Tregs can play 
a major role.  
It has been shown that Tregs migration from thymus to the SLT and then 
to the site of antigen challenge is vital to their function (73). This 
compartmentalization is largely governed by the chemokines, which are small 
secreted cytokines, acting via their specific transmembrane receptors. It has been 
shown that Tregs possess specific chemotactic potential that is different from the 
effector T cells. Iellem et al reported in healthy individuals that Tregs show 
specific expression of the chemokine receptors CCR4 and respond to its ligands 
CCL17 and CCL22 in the supernatant of maturing dendritic cell culture (37). 
However, antigen presentation and activation of TCR in all T cells leads to up-
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regulation of CCR4 and CCR8, with the ability to respond to corresponding 
chemokines CCL17 and CCL1 (145). Hence, secretion of these chemokines by 
various inflammatory cells such as activated dendritic cells within the allograft 
may lead to a competitive migration of both the effector cells and Tregs.  This 
may explain my results of a significant association between CCL17 and CD4+ 
lymphocytic infiltration in the rejecting allograft.  
My limited data shows the presence of Tregs in the rejecting 
endomyocardial biopsy tissue only, while CD4+ cells were present in non-
rejecting samples as well. Despite the small number of cases in my series, the 
finding is consistent with a previous study by Dijke et al showing an association 
between acute rejection and FOXP3 mRNA expression within the 
endomyocardial biopsies from heart transplant recipients (257). Similar work in 
renal (258) and liver  allograft recipients (259) also showed an increase in 
FOXP3+ Tregs in the allograft during acute cellular rejection. Taken together, 
these findings suggest that Tregs form part of the cellular infiltrate during acute 
rejection, probably in an attempt to suppress the effector response. However, the 
study by Veronese et al with a large cohort of 80 human renal transplant 
recipients demonstrated no beneficial effect in survival with Treg infiltrate 
during acute cellular rejection (258). Hence, the significance of Treg infiltration 
and its association with the outcome following acute rejection, chronic rejection 
or long term survival in transplant recipients is yet to be established. 
Despite this uncertainty, an understanding of and attempts to manipulate 
the physiological differences between effector and regulatory T cells present 
exciting new opportunities for tolerance induction following transplantation. In 
this regards, knowing exact chemokine pathways that lead to Treg migration to 
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the allograft bears significant importance. This is an established fact that Tregs 
sow specific migration towards the allograft. Schmidt-Lucke et al recently 
documented via trans-cardiac gradient specific uptake of Tregs in the cardiac 
allografts (255). They were the first to demonstrate the actual presence of 
FOXP3+ Tregs in the human cardiac allografts using double 
immunofluorescence labelling. However, they did not investigate the 
chemotactic pathway responsible for Treg migration, and also did not compare 
the results between rejecting versus non-rejecting biopsies. My data is unique in 
the sense that we have provided a serial, objective assessment of CD4+FOXP3- 
counts, Treg counts, and CCL17 expression in a cohort of heart transplant 
recipients in both rejecting and non-rejecting states.  
Studies on murine knock-out models has paved way to targeting specific 
cytokines and chemokines in various inflammatory, neoplastic and transplant 
condition (131, 260, 261). Most of the transplant experiments involved blocking 
one or two chemokine pathways, hence leading to reduced effector cell infiltrate 
and prolonging allograft survival. However, it has not yet been possible to 
augment a specific chemokine expression that could lead to isolated effects on 
desirable cell population within the body. This is due to the fact that chemokine 
system is quite redundant, with several overlapping pathways operating together. 
The aim of my study was to determine if CCL17 could provide unique 
chemotactic response to the Tregs in isolation. However, I found that CCL17 
expression is also correlated with the infiltration of CD4+FOXP3-cells. In 
addition, the ratio of Treg: CD4+FOXP3- cells did not show any correlations 
with CCL17. A corroborative example comes from the study on murine models 
of colonic carcinoma where intra-tumoral injections of mutant adenoviral 
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vectors encoding for CCL17 caused significant effector T cells and macrophage 
infiltration, leading to tumour regression (262). Hence, any immune therapy 
using CCL17 to guide Tregs into the allograft may invariably lead to effector 
cell infiltration, and provoke a worse outcome.  
One of the major limitations of my study was that it was hugely 
underpowered to detect substantial changes in chemokines or cellular 
infiltrations. The obvious reasons were ability to obtain the required serial 
samples to run the histological tests in this novel study. Another limiting factor 
was that some sections from the FFPE samples might have missed the level 
where lymphocytic infiltration was present. This might have had an effect on 
staining both the CD4+FOXP3- cells and the Tregs, and is the likely explanation 
of the inability to identify the cells in two rejecting samples. 
In conclusion, my limited observational study shows that FOXP3+ Tregs 
infiltrate the myocardium during acute rejection in human heart transplant 
recipients. Treg and CD4+FOP3- infiltration during acute rejection is 
significantly associated with CCL17 expression in the allograft. Further studies 
will determine long term effects of CCL17 expression on allograft vasculopathy 
and long term survival. 
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Chapter 7 Conclusion 
This is the first study to explore the chemotactic response of Tregs in 
human heart transplant recipients. The results of this study show that acute 
rejection following heart transplantation leads to an up-regulation of peripheral 
blood Th1 chemokine levels. I have further shown in stable heart transplant 
recipients that peripheral blood CD4+CD25brightFOXP3+ lymphocytes show 
specific and dose dependent migration in response to Th2 chemokine CCL17 
and Th1 chemokine CCL5, in contrast to the effector T cells which migrate in 
response to CCL19. Through double immunofluorescence labelling and 
immunohistochemistry I have also shown that in-vivo migration of Tregs to the 
allograft is associated with CCL17 secretion.  
Tregs, first described by Sakaguchi et al as naturally occurring 
CD4+CD25+ cells capable of maintaining self tolerance, are now widely 
recognized as the prime tolerance mediating cells following transplantation (33, 
34, 263, 264). In fact, experimental studies have documented a role for Treg 
immunotherapy in transplant models with some success (245, 265). Any such 
attempt in humans needs extra caution and thorough understanding of the 
physiological alterations in Tregs under varying conditions.  
Mindful of the fact that Tregs mechanism of action involves close cell-
cell contact, Treg migration in vivo has been scrutinized by several authors (73, 
240). Naïve like Tregs circulate to the antigen presenting sites under the 
influence of CCL19 and CCL21, where they co-localize with antigen presenting 
cells (APC) (50, 124). This interaction not only activates Tregs via t cell 
receptor (TCR) stimulation, but also leads to up-regulation of CCR4 and CCR8, 
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the receptors for CCL17 and CCL22 secreted by the APC (145). Also, the same 
chemokines are secreted by various inflammatory cells within the site of antigen 
challenge, leading to the peripheral migration of Tregs (266). My data shows 
CCL17 staining within the myocardium during both stable and rejecting states, 
with significant association between CCL17 and Treg infiltration during acute 
rejection. However, the chemotactic effect of CCL17 is not exclusive to Tregs, 
since CD4+FOXP3- cells also showed strong correlation with CCL17 expression 
during acute rejection. This suggests that CCL17 secretion forms part of the 
alloresponse during acute rejection, leading to migration of both the effector and 
regulatory cells within the allograft. 
I have further demonstrated that acute rejection in heart transplant 
recipients leads to a significant rise in the peripheral blood levels of specific Th1 
chemokines, including CCL2, and CCL5. Intragraft expressions of these 
chemokines have been associated with acute rejection; however, association 
with peripheral blood levels was never established before (91, 98). Using in-
vitro chemotaxis study we further demonstrated that CCL5 causes specific 
migration of Tregs but not of the CD4+CD25- effector cells. Taken together, it 
suggests that CCL5, which is an inflammatory Th1 chemokine secreted by 
various inflammatory cells including APC, may have an important role in Treg 
migration during acute rejection. Further studies may investigate the balance 
between CCL17 and CCL5 stimuli during stable and acute rejection following 
transplantation. 
Transplant poses a different environment not only due to the alloantigen 
presentation, but also from various immunosuppressive medications. My results 
demonstrate that Tregs in stable heart transplant recipients are unaffected by 
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various immunosuppressive drugs. However, a surprising result in my study was 
that the use of statins was associated with significantly reduced Treg counts. 
Statins are commonly used in transplant recipients to counter hyperlipidaemia in 
an effort to prevent allograft vasculopathy and prolong survival (214, 237). 
Statins are pleiotropic molecules, with the ability to affect, either directly or 
indirectly, several immune cells and cytokines (215). Since both statins and 
Tregs reduce the burden of atherosclerosis following heart transplantation (236), 
the findings of my study need further exploration. It is uncertain whether statins 
lead to a decreased population of Tregs associated with other compensatory 
mechanisms or they cause Treg migration to the allograft. 
This study further highlighted the problems of conducting such 
investigations in humans. In particular, co-localizing Treg cellular markers in 
the precious biopsy tissues posed a significant challenge due to various reasons, 
including high autofluorescence from FFPE samples and non-specific staining 
from experimental or polyclonal antibodies. Somewhat similar observations 
have been made by previous authors (255). Hence, further dissection of other 
chemokine pathways within the allograft was not possible, which formed a 
limitation of my study. 
In summary, I have demonstrated for the first time an association 
between the presence of Tregs within rejecting myocardium and the chemokine 
CCL17. The absence of Tregs from the non-rejecting hearts suggests Treg 
infiltration as part of the alloresponse. Prospective longitudinal studies will have 
to determine the fate and function of these cells in the development of CAV and 
long term survival. Therapeutic manipulations to augment selective Treg 
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migration may provide exciting opportunities to reduce the incidence of acute or 
chronic rejection and perhaps, induce tolerance.  
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